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“If we do not take change by the hand it will surely take us by the throat.” 
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ABSTRACT  
 
The main goal of this work was to create a valuable Risk Management Approach that 
enables a Process Validation over products lifecycle. Quality risk management (QRM) has been 
described in regulatory guidance for several aspects of process validation, such as product 
lifecycle, extent of validation, determination of critical quality attributes (CQAs) and critical 
process parameters (CPPs), process design space (DS), and sampling plans and statistical 
confidence levels. Verification of the process in every single produced batch, over the product 
life time is now an expectation from regulatory authorities.  
Based on this Hikma is required to implement a Process Validation as collection and 
evaluation of data, from the process design phase and continuing through commercial 
production phase, establishing scientific evidence that a process is in state of control and 
therefore capable of consistently and effectively assure product quality. Since pharmaceutical 
products and processes are complex and multivariate by nature, a scientific understanding of 
relevant multi-factorial relationships requires risk-based approach. In this context, a risk 
management approach to assess risk of injectable products manufacturing was created.  The 
aim is to reduce or even eliminate potential failures and make more resourceful and efficient, 
qualitatively and quantitatively, processes over lifecycle.  
The goal was successfully achieved, and a systematic process for the assessment, control, 
communication and review of risks, targeting the highest quality of an injectable product is now 
available to be applied - Hikma Process Validation Program of Injectable Products Lifecycle. 
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RESUMO 
 
O principal objetivo deste trabalho foi criar uma ferramenta valiosa para uma abordagem 
de Gestão de Risco que permita Validação de Processos em todo o ciclo de vida do produto. A 
Gestão da qualidade e do Risco tem sido descrita nos guias regulatórios por diversos aspetos 
da validação de processo, como o ciclo de vida do produto, a extensão da validação, a 
determinação dos atributos críticos de qualidade (CQAs) e dos parâmetros críticos do processo 
(CPPs), espaço de desenho do processo (DS), planos de amostragem e intervalos estatíscos 
de confiança. A verificação do processo em cada lote produzido ao longo do tempo de vida do 
produto é agora uma expectativa das autoridades reguladoras.  
Com base nisto é necessário que a Hikma implemente a Validação de Processo como 
uma coleção e avaliação de dados, desde a fase de desenho do processo e continuamente 
durante a fase de produção comercial, estabelecendo evidências científicas que o processo 
está em estado controlado e que por isso é capaz de consistentemente e eficientemente 
assegurar um produto de qualidade. Sendo que os produtos e processos farmacêuticos são 
complexos e multivariados por natureza, um entendimento científico das relações multi-
factoriais relevantes pede uma abordagem baseada no risco. Neste contexto, foi criada uma 
abordagem de gestão de risco para avaliar o risco da produção de produtos injetáveis. A 
finalidade é reduzir ou até mesmo eliminar potenciais falhas e facultar ao processo mais 
recursos e tona-lo mais eficiente, qualitativamente e quantitativamente, durante o seu ciclo de 
vida. 
O objetivo foi alcançado com sucesso, e um processo sistemático de avaliação, controlo, 
comunicação e revisão dos riscos com o alvo da máxima qualidade do produto injetável está 
agora disponível para ser aplicado – Programa de Validação de Processo Hikma do Ciclo de 
Vida dos Produtos Injetáveis.  
 
 
 
Palavras-chave: Qualidade, Validação, Ciclo-de-vida, Risco, Processo, Ferramentas 
 
  
vii 
 
TABLE OF CONTENTS 
 
ACKNOWLEGEMENTS .............................................................................................................. iv 
ABSTRACT...................................................................................................................................v 
RESUMO......................................................................................................................................vi 
LIST OF ABBREVIATIONS .......................................................................................................... x 
LIST OF FIGURES ...................................................................................................................... xii 
LIST OF TABLES ...................................................................................................................... xiv 
Chapter 1 INTRODUCTION ....................................................................................................... 1 
Chapter 2 LITERATURE OVERVIEW ....................................................................................... 2 
2.1. Process Validation and Guidelines Chronology ............................................................ 2 
2.2. Process Validation Key Concepts ................................................................................. 6 
2.3. Reasons to Validate Process / Regulatory Requirements ............................................ 8 
2.4. Manufacturing Process Validation over Products Lifecycle .......................................... 9 
2.4.1. STAGE 1: Process Design ...................................................................................... 10 
2.4.2. STAGE 2: Process Qualification ............................................................................. 14 
2.4.3. Stage 3: Continued Process Verification (CPV) ...................................................... 22 
2.5. Connection of Process Validation, Quality System and Quality Risk Management ... 25 
2.5.1. Risk Assessment ..................................................................................................... 28 
2.5.2. Risk Control ............................................................................................................. 29 
2.5.3. Risk Review ............................................................................................................. 30 
2.5.4. Risk Communication ................................................................................................ 30 
2.6. Products’ risk framework as part of Manufacturing Process Validation ...................... 31 
Chapter 3 INJECTABLE PRODUCTS OVERVIEW ................................................................ 34 
3.1 Nomenclature and definitions ...................................................................................... 34 
3.2 Vehicles and Added substances ................................................................................. 35 
3.3 Aseptic Manufacturing ................................................................................................. 35 
3.3.1 Visual inspection ...................................................................................................... 36 
3.3.2 Containers ............................................................................................................... 37 
3.3.3 Closures .................................................................................................................. 37 
viii 
 
3.3.4 Labelling .................................................................................................................. 37 
3.4 Injections ..................................................................................................................... 38 
3.5 Intravenous infusions .................................................................................................. 39 
3.6 Implants ....................................................................................................................... 39 
3.7 Powders for injections ................................................................................................. 40 
Chapter 4 PARAMETERS AND METHODS – Quality Risk Management Tools ................. 43 
4.1 Critical Parameters ...................................................................................................... 43 
4.2 Identifying Process Variation ....................................................................................... 44 
4.2.1 The Four Process States ......................................................................................... 45 
4.3 Control Charts ............................................................................................................. 46 
4.3.1 Elements of a Control Chart .................................................................................... 47 
4.3.2 Controlled Variation ................................................................................................. 48 
4.3.3 Uncontrolled Variation ............................................................................................. 48 
4.3.4 Control Charts for Continuous Data ........................................................................ 49 
4.3.5 Control Charts for Discrete Data ............................................................................. 51 
4.3.6 Selection of a Control Chart .................................................................................... 54 
4.4 Control Charts as a Tool for Analysis .......................................................................... 55 
4.4.1 Within-subgroup Variation ....................................................................................... 55 
4.4.2 Between Subgroup Variation ................................................................................... 56 
4.4.3 Xbar Chart – other use ............................................................................................ 56 
4.5 Risk Management Tools Overview .............................................................................. 57 
4.5.1 Product Prioritization Matrices (PPM) ..................................................................... 57 
4.5.2 Preliminary hazard Analysis (PHA) ......................................................................... 58 
4.5.3 Risk Analysis and Mitigation Matrix (RAMM) .......................................................... 58 
4.5.4 Failure Mode Effects Analysis (FMEA) .................................................................... 60 
4.5.5 Failure Mode Effects and Criticality Analysis (FMECA) .......................................... 61 
4.5.6 Analytical Hierarchy Process (AHP) ........................................................................ 61 
4.5.7 Hazard Analysis and Critical Control Points (HACCP) ............................................ 63 
Chapter 5 RESULTS – Assess Products` Risk Framework ................................................ 65 
5.1 Injectables Manufacturing Processes.......................................................................... 65 
5.2 Injectable Manufacturing Variables: Sources .............................................................. 66 
ix 
 
5.3 Critical Process Parameters (CPPs) ........................................................................... 67 
5.4 Hikma Risk Approach – Assess Products` Risk Framework over entire Product 
Lifecycle ................................................................................................................................... 69 
5.5 HIKMA CASE STUDIES – Risk Approach Implementation ........................................ 94 
5.5.1 Aqueous solutions ................................................................................................... 94 
5.5.2 Oils........................................................................................................................... 98 
5.5.3 Lyophilized Products ............................................................................................. 102 
5.5.4 Suspensions .......................................................................................................... 106 
Chapter 6 GENERAL DISCUSSION...................................................................................... 108 
Chapter 7 CONCLUSIONS .................................................................................................... 110 
Chapter 8 FUTURE PERSPECTIVES ................................................................................... 111 
REFERENCES .......................................................................................................................... 112 
APPENDIX... ................................................................................................................................. 1 
 
  
x 
 
LIST OF ABBREVIATIONS 
 
AHP Analytical Hierarchy Process 
CAPA Corrective Action Preventive Action 
CCP Critical Control Parameters 
cGMP Current Good Manufacturing Practices 
CMAs Critical Material Attributes 
CPP Critical Process Parameter 
CPV Continued Process Verification 
CQA Critical Quality Attribute 
DS Design Space 
EMA European Medicines Agency 
FDA U. S. Food and Drug Administration 
FMEA Failure Modes and Effects Analysis 
FMECA Failure Modes, Effects and Criticality Analysis 
HACCP Hazard Analysis and Critical Control Points 
IPC In Process Control 
IQ Installation qualification 
NOR Normal Operating Range 
OOC Out-of-control 
OQ Operational performance qualification 
PAR Proven Acceptable Range 
PAT Process Analytical Technology 
PDA Parenteral Drug Association 
PQ Product performance qualification 
PQS Pharmaceutical Quality System 
PV Process Validation 
PVP Process Validation Protocol 
xi 
 
PVR Process Validation Report 
QbD Quality by Design 
QRM Quality Risk Management 
QRM Quality Risk Management 
QS Quality System 
QS Quality System 
QTPP Quality Target Product Profile 
RAMM Risk Analysis and Mitigation Matrix 
RTRT Real-Time Release Testing 
SAB Scientific Advisory Board 
SOPs standard operating procedures 
 
  
xii 
 
LIST OF FIGURES 
 
Figure 1: Chronogram of Process Validation and risk concept evolution. ................................... 4 
Figure 2: Scheme representing the Process Manufacturing and the relationship between CPPs, 
Design Space, Controls and CQAs. .............................................................................................. 6 
Figure 3: Proven Acceptable Range (PAR). ................................................................................ 7 
Figure 4: Knowledge space containing the Design space and NOR. .......................................... 8 
Figure 5: Process Validation – Life Cycle Approach .................................................................. 10 
Figure 6: A Process design approach incorporating Quality by Design ..................................... 11 
Figure 7: A quality by design approach to product and process development .......................... 12 
Figure 8: Some common utilities used in Hikma plants ............................................................. 14 
Figure 9: Scheme exemplifying Process Validation Sampling over Product Lifecycle .............. 20 
Figure 10: Risk-Based Validation Lifecycle ................................................................................ 21 
Figure 11: Quality system Hierarchy .......................................................................................... 23 
Figure 12: Challenges: Artefacts are found in data review – Trend. .......................................... 25 
Figure 13: Challenges: Artefacts are found in data review – Bimodal results. .......................... 25 
Figure 14: Diagram of the ICH Q10 Pharmaceutical Quality System Model ............................. 26 
Figure 15: Overview of a typical quality management process .................................................. 27 
Figure 16: Sterility as CQA of an injectable product and sources of variability that should be 
controlled. .................................................................................................................................... 28 
Figure 17: Aseptic process using a risk-based approach - contamination control. .................... 30 
Figure 18: Systems of a Quality Risk Management ................................................................... 31 
Figure 19: Schema for Identification and Control of variations in manufacturing process and 
product quality ............................................................................................................................. 32 
Figure 20: Differences in Particle sizes between a “True solution”, a Colloidal solution” and 
“Suspensions”.............................................................................................................................. 38 
Figure 21: Suspension and the phenomenon of caking which shows that suspensions are 
thermodynamically instable systems. .......................................................................................... 39 
Figure 22: Process Flow Diagram: The Lyophilization Process ................................................. 41 
Figure 23: Process development Parameters – PAR (Proven Acceptable Range) and CpK 
(Process Capability Factor) – understanding of the process ...................................................... 44 
Figure 24: Process development Parameter – CpK (Process Capability Factor) – Controlled 
and Uncontrolled Process. .......................................................................................................... 44 
Figure 25: General Concept for Fishbone (Ishikawa) diagram (or Cause and Effect Diagram). 45 
Figure 26: Four Process States.................................................................................................. 46 
Figure 27: Natural Process Degradation .................................................................................... 46 
Figure 28: Elements of a Control Chart ...................................................................................... 47 
Figure 29: Example of Controlled Variation ............................................................................... 48 
Figure 30: Example of Uncontrolled Variation ............................................................................ 48 
Figure 31: Relationship of Control Chart to Normal Curve ........................................................ 49 
xiii 
 
Figure 32: Example of Individuals and Moving Range (I-MR) Chart .......................................... 50 
Figure 33: Example of Xbar and Range (Xbar-R) Chart ............................................................ 50 
Figure 34: Example of c-Chart ................................................................................................... 52 
Figure 35: Example of u-Chart ................................................................................................... 52 
Figure 36: Example of np-Chart ................................................................................................. 53 
Figure 37: Example of p-Chart ................................................................................................... 53 
Figure 38: Mechanism for selection of the appropriate Control Chart ....................................... 54 
Figure 39: Within Subgroup Variation ........................................................................................ 55 
Figure 40: Example of R Chart ................................................................................................... 56 
Figure 41: Between Subgroup Variation .................................................................................... 56 
Figure 42: Xbar Chart within Variation ....................................................................................... 56 
Figure 43: Risks hierarchy .......................................................................................................... 57 
Figure 44: HACCP Seven Principles .......................................................................................... 64 
Figure 45: Flow-chart e.g. of an Injectable Manufacturing Process ........................................... 65 
Figure 46: Cause and Effect Diagram with CPP from Manufacturing Process of Injectable 
Products ...................................................................................................................................... 66 
Figure 47: Strategy approach for products design space verification over lifecycle of different 
forms of Hikma Injectable Products - Hikma Process Validation Program of Injectable Products 
Lifecycle.; no temporal relationship is intended. ......................................................................... 69 
Figure 48: Hikma 9 Steps Approach for Products Risk Assessment ......................................... 71 
Figure 49: Detectability of risk over product lifecycle determined based on people experience.
 ..................................................................................................................................................... 72 
Figure 50: Example of a risk assessment to be used in a process validation plan .................... 87 
Figure 51: IPC assay for bulk solution of produced batches for an oil basis product. ............... 98 
Figure 52: Hikma risk assessment tool applied for this Oil case – Priority RISK: Transfer liquid 
RM with high viscosity into the preparation tank – “High RISK further tests and controls 
required” ...................................................................................................................................... 99 
Figure 53: Graph showing the criticality levels for the studied process steps. ........................ 100 
Figure 54: Graph showing the RPN results for the studied process steps. ............................. 101 
Figure 55: IPC assay for bulk solution of produced batches for an oil basis product – after 
controls had been implemented to the compounding process. ................................................. 102 
Figure 56: Unstable size change for suspension “BetaM” ....................................................... 106 
Figure 57: Particle sizes of the last produced Suspensions “BetaM”....................................... 106 
Figure 58: Stable size change for suspension “BetaM” ........................................................... 107 
 
 
 
 
xiv 
 
LIST OF TABLES 
 
Table 1: CPPs and CQAs summing up description ...................................................................... 7 
Table 2: Control Limit Calculations ............................................................................................. 51 
Table 3: Constants for calculation Control Limits ....................................................................... 51 
Table 4: Typical PHA worksheet................................................................................................. 58 
Table 5: CQAs and relative criticality .......................................................................................... 59 
Table 6: Short e.g. of process parameters with CQAs with risk scores detailed for just one 
process step (compounding). ...................................................................................................... 60 
Table 7: Specifications of Process Parameters and general IPC and Finish Product Controls . 67 
Table 8: Key to construct the assessment tool for each product ................................................ 73 
Table 9: Calculation for Criticality ............................................................................................... 73 
Table 10: Calculation of Risk Priority Number (RPN) ................................................................. 74 
Table 11: Risk Assessment for Hikma Injectable Products – Critical Process Parameters ....... 75 
Table 12: Risk of citric acid losses during compounding mitigation ........................................... 95 
Table 13: Process Parameters that might impact CQAs – Purity and Solubility ...................... 103 
Table 14: CPPs that impact purity and solubility (CQAs) in Finished Product ......................... 104 
Table 15: Continuous Process Verification approach for a Lyophilized Product ...................... 105 
Table 16: PHA worksheet for a suspension with low density results ....................................... 107 
 
 
Chapter 1   INTRODUCTION 
1 
 
Chapter 1 INTRODUCTION 
 
Process validation is used to confirm that the resulting product from a specified process 
consistently conforms to product requirements. A risk-based approach helps to identify crucial 
parameters as sources of process variation that affect product quality. Controlling the sources of 
variation commensurate with the risk they represent to the process and final product attributes 
are the key concepts of assessing products` quality framework. 
The next chapter – LITERATURE OVERVIEW – has the purpose of giving the background 
required to understand the issues addressed in the later chapters, therefore the focus is mainly 
on process validation, risk management and critical process parameters impact on injectables 
products quality. Following this, the chapter – PARAMETERS AND METHODS – Quality Risk 
Management Tools presents general statistical methods and tools for risk analysis and process 
variability. 
Afterwards, in the subsequent chapter – RESULTS – Assess Products` Risk Framework is 
presented, followed by one section containing the tool application to Hikma products and the 
discussion of the data, respectively. This work focuses on how a science- and risk-based 
approach toward process validation can be created and how such an approach can alleviate 
potential sources of failures. As final chapters, conclusions and future perspective are 
presented. 
The work behind this thesis was performed in Hikma Farmacêutica S.A., Portugal and 
Thymoorgan Pharmazie GmbH, Germany. 
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Chapter 2 LITERATURE OVERVIEW 
 
When a new process and product are developed or there is an attempt to understand an 
existing process, knowing how materials, processes and controls affect the final product is 
essential (Brindle, et al., 2012). 
 
2.1. Process Validation and Guidelines Chronology 
 
The concept of Process Validation has been changing over the last decades. In 1987 FDA 
(U. S. Food and Drug Administration) issued Guidance for Process Validation (Guideline on 
General Principles of Process Validation, May, 1987) (Figure 1) in order to drive industries to 
reflect on process validation best practices. This Guidance defined the types of validations as 
Prospective and Retrospective; also defined the IQ (Installation qualification) including 
subjectively OQ (Operational qualification) and PQ (Process qualification)
1
; and enlightened 
worst case scenario studies, Process Revalidation and Process Validation as a multiple batch 
demonstration (FDA, 2009). However, in the latest FDA guidelines this old IQ/OQ/PQ approach 
doesn`t demonstrate the process itself; equipment function is barely half of the story. There are 
raw materials and inputs, process controls, and product attributes associated with every unit 
operation in a manufacturing process. 
 
In the past, the types of process validation were defined in terms of when they occur in 
relation to product design, transfer to production and release of the product for distribution. 
Prospective validation was defined as the validation carried out during the development stage 
by means of a risk analysis of the production process, which is broken down into individual 
steps: these are then evaluated on the basis of past experience to determine whether they 
might lead to critical situations. Where possible critical situations are identified, the risk is 
evaluated, the potential causes are investigated and assessed for probability and extent, the 
trial plans are drawn up, and the priorities set. The trials are then performed and evaluated, and 
an overall assessment is made. If, at the end, the results are acceptable, the process is 
satisfactory. Unsatisfactory processes must be modified and improved until a validation exercise 
proves them to be satisfactory. Retrospective validation was a concept that used to involved the 
examination of past experience of production on the assumption that composition, procedures, 
and equipment remain unchanged; such experience and the results of in-process and final 
control tests are then evaluated. Recorded difficulties and failures in production are analyzed to 
determine the limits of process parameters. A trend analysis used to be conducted to determine 
                                                     
1 Installation qualification (IQ): establishing documented evidence that process equipment and ancillary systems are capable of consistently operating within 
established limits and tolerances. Operational performance qualification (OQ): establishing documented evidence that the process is effective and 
reproducible. Product performance qualification (PQ): establishing documented evidence through appropriate testing that the finished product produced by a 
specified process(es) meets all release requirements for functionality and safety (FDA, 2009). 
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the extent to which the process parameters are within the permissible range. Retrospective 
validation is obviously not a quality assurance measure in itself, and should never be applied to 
new processes or products.  
Also, 1987 guidance included the concept of revalidation of processes when changes to a 
process are introduced, or when process variation is detected. Revalidation ensured that 
changes in the process and/or in the process environment, whether intentional or unintentional, 
do not adversely affect process characteristics and product quality. A Revalidation could be 
performed after any change having a bearing on product quality or periodically carried out at 
scheduled intervals. 
But the concept of worst-case conditions for Process validation was a key theme of the 
1987 guidance – “A set of conditions encompassing upper and lower limits and circumstances, 
including those within standard operating procedures, which pose the greatest chance of 
process or product failure when compared to ideal conditions.  
 
The basic Principles for Process Validation according to 1987 Guidance on General Principles 
of Process Validation can be stated as follows: 
 Establish that the process equipment has the capability of operating within required 
parameters; 
 Demonstrate that controlling, monitoring, and/or measuring equipment and 
instrumentation are capable of operating within the parameters prescribed for the process 
equipment; 
 Perform replicate cycles (runs) representing the required operational range of the 
equipment to demonstrate that the processes have been operated within the prescribed 
parameters for the process and that the output or product consistently meets 
predetermined specifications for quality and function; and 
 Monitor the validated process during routine operation. As needed, re-qualify and recertify 
the equipment. 
 
The most recent approach (Guidance for Industry - Process Validation: General Principles 
and Practices, January 2011) describes three stages of process validation during the lifecycle of 
a drug, which falls into ICH Q8 (Guidance for Industry - Q8 Pharmaceutical Development, May 
2006) (Figure 1). During early product and processes development, process design builds 
criteria for testing, qualification, and setting specifications on. Process qualification 
encompasses many validation concepts familiar to those who have been working with the 
previous guidance document all along: Manufacturing equipment, tooling, and instrumentation, 
and utilities must be qualified using standard validation protocols along with an associated 
validation master plan, risk assessment, and requirements specifications. Continued process 
verification, the final stage, is the ongoing assurance gained during routine production that the 
process remains in state of control (Section 2.4 - Manufacturing Process Validation over 
Products Lifecycle).   
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Figure 1: Chronogram of Process Validation and risk concept evolution.  
After some years in which companies applied this 1987 guideline, there was one question 
still to be answered: If validation provides a high degree of assurance that the process works 
reliably and predictably, then why do processes fail during commercial manufacture? And the 
answer was afterwards clear - Process Variation. 
In 2006 FDA notified industry, and issued, in draft Nov. 17, 2008 “reflection of industry 
practice” and PDA (Parenteral Drug Association) SAB (Scientific Advisory Board) formed a 
committee to collect and collate member comments. In January, 2011 FDA issued new 
guidance for industry regarding process validation (Guidance for Industry - Process Validation: 
General Principles and Practices, January 2011) (Figure 1). 
 
In the past, process validation emphasis has been on collecting large quantities of data 
from process validation batches, leading to a perception of process validation as largely a 
documentation exercise. The updated approach requires the manufacturer to collect data 
through the product lifecycle and evaluate it for evidence that it supports a quality and in state of 
control process. 
The 2011 guidance revised the concept of revalidation of processes with the introduction of 
Continued Process Verification (Section 2.4.3 - Stage 3: Continued Process Verification (CPV)). 
Also Retrospective validation is not mentioned. The worst case concept was removed and the 
expectations changed, as follows: 
The commercial manufacturing process and routine procedures must be followed. The 
Process Qualification batches (equivalent to their previous name “Process Validation batches”) 
should be manufactured under normal conditions by personal expected to routinely perform 
each step of each unit operation in the process. 
Chapter 2   LITERATURE OVERVIEW 
5 
 
Nowadays, Process Validation is focused on product quality through processes 
understanding and control: “Process validation is defined as the collection and evaluation of 
data, from the process design stage through commercial production which establishes scientific 
evidence that a process is capable of consistently delivering quality product.”(Guidance for 
Industry - Process Validation: General Principles and Practices, January 2011). 
In summary the significant changes from the last approach for process validation are listed 
below and are also detailed on Section 2.4 - Manufacturing Process Validation over Products 
Lifecycle. 
 Add emphasis to process design; 
 Include discussion of risk; 
 Involve activities over the entire process lifecycle (ongoing program, in three defined 
stages); 
 Emphasizes the role of objective measures and statistical tools; 
 Emphasizes the knowledge, detection and control of variability. 
 
EMA (European Medicines Agency) published the long-announced revision of its Guideline 
on Process Validation as draft on March 2012. The final version will replace the current 
guideline "Note for Guidance on Process Validation (CPMP/QWP/848/96, 
EMEA/CVMP/598/99). The aim was to include modern aspects of GMP. The concept paper has 
mentioned ICH Guidelines Q8 (Guidance for Industry - Q8 Pharmaceutical Development, May 
2006), Q9 (Guidance for Industry - Q9 Quality Risk Management, June 2006) and Q10 
(Pharmaceutical Quality System - ICH Q10, 2011), Process Analytical Technology (PAT), 
Quality by Design (QbD), Real-Time Release Testing (RTRT). It has already been announced 
that the revision will add an "enhanced" approach and "continuous process verification" to the 
current traditional approach as described in ICH Q8 (Guidance for Industry - Q8 Pharmaceutical 
Development, May 2006). The annexes of the current Note for Guidance will be included in the 
revised guideline and a harmonisation with the current FDA Guidance on Process Validation is 
recommended (Pommeranz, 2012). Some differences exist between the issued FDA guidance 
and the draft of the EMA guideline. 
In the last months FDA recommended to the pharmaceutical industries to have Operational 
Metrics systems under their pharmaceutical quality system. In a different angle but with the 
same aim (ensure product quality at commercial scale) FDA proposes Design Space 
Verification.   
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2.2. Process Validation Key Concepts 
 
Manufacturing Process is “the sequence of activities, people, and systems involved in 
achieving some desired result”. 
Operating Parameters are the conditions under which a process is performed. This 
conditions can be physical or chemical (pH, temperature, pressure, agitator rpm, flow rate, etc.). 
Process parameters are usually controlled within defined operating ranges to set-point values. 
 
There are some measured product attributes that are deemed critical to ensure the quality 
requirements of either an intermediate or final product. The identified attributes are termed 
Critical Quality Attributes (CQAs) (Process Robustness - A PQRI White Paper, 2006).  CQAs 
are the physical, chemical, biological, or microbiological property or characteristic that should be 
within a predetermined range to ensure the desired product quality (Guidance for Industry - Q8 
Pharmaceutical Development, May 2006). Not all process outputs (acceptance criteria and 
specifications) are CQAs.  
During development, process characterization studies identify the Critical (or Key) 
Process Parameters (CPPs). Critical Process parameters is a process input that, when varied 
beyond a limit range has an impact with significant influence on a critical quality attribute (CQA) 
and therefore should be monitored or controlled to ensure that the process produces the 
desired quality (Figure 2) (Guidance for Industry - Q8 Pharmaceutical Development, May 
2006). Failure to stay within the defined range of the CPP leads to a high likelihood of failing to 
conform to a CQA. 
 
Figure 2: Scheme representing the Process Manufacturing and the relationship between CPPs, Design Space, Controls 
and CQAs. 
 
It is also important to distinguish between parameters that affect critical quality attributes 
and parameters that affect the efficiency, yield, or worker safety or other business objectives; 
those are Non Critical (non Key) Process Parameters unless they also impact product 
quality.  
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Control procedures shall be established to monitor the output and to validate the 
performance of those manufacturing parameters that may be responsible for causing variability 
in the characteristics of in-process material and the drug product (Title 21 - Food and Drugs 
Chapter I - Food and Drug Administration Department of Health and Human Services 
subcharpeter C- Drugs - General, April 2013). 
 
Table 1: CPPs and CQAs summing up description 
CPPs CQAs 
Typically, set-point with an operating range Acceptance Criteria / Specifications 
Inputs (also raw-materials or components) Outputs (in-process material, intermediates or 
final product) 
Controlled to achieve consistent, repeatable, 
reliable results 
Used to demonstrate process control, 
repeatability, and reliability 
 
During early stages of a process development, parameter target values and tolerance limits 
are based on good scientific rationale and experimental knowledge gained from laboratory and 
pilot scale studies. A parameter that shows a strong relationship to a critical quality attribute 
becomes a key focal point for further study. In developing the manufacturing science, a body of 
experimental data is obtained, and the initially selected parameter tolerances are confirmed or 
adjusted to reflect the data. This becomes the Proven Acceptable Range (PAR) for the 
parameter, and within the PAR an operating range is set based on the typical or Normal 
Operating Range (NOR) for the given parameter (Figure 3). PAR becomes the Design space 
if there is a multidimensional combination and interaction of input variables (e.g. material 
attributes) and process parameters that have been demonstrated to provide quality assurance 
(Figure 5). Knowledge space is a summary of all process knowledge obtained during product 
development. Tolerance ranges may be rationalized and adjusted as increased process 
understanding is gained (Process Robustness - A PQRI White Paper, 2006).  
Further study of parameters is a prelude to determining those that are critical process 
parameters. If varying a parameter beyond a limited range has a detrimental effect o a critical 
quality attribute, it is defined as a Critical Process Parameter (CPP). A cause-effect relationship 
may be established for parameters and desired attributes.  
 
Figure 3: Proven Acceptable Range (PAR). 
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Figure 4: Knowledge space containing the Design space and NOR. 
Quality is the degree to which a set of inherent properties of a product, system, or process 
fulfils requirements.  
State of control is a condition in which the set of controls consistently provides assurance 
of continued process performance and product quality (Pharmaceutical Quality System - ICH 
Q10, 2011). 
Capability of a process is the ability of a process to produce a product that will fulfil the 
requirements of that product. The concept of process capability can also be defined in statistical 
terms. 
 
2.3. Reasons to Validate Process / Regulatory Requirements 
 
The cGMP regulations require that manufacturing processes be designed and controlled to 
guarantee that materials and finish product meet pre-determined quality requirements and do so 
consistently and reliably. This regulation requires manufacturers to design a process, including 
operations and controls, which results in a product meeting these attributes (Guidance for 
Industry - Process Validation: General Principles and Practices, January 2011). 
Nevertheless there are other reasons in addition to the regulatory requirements (cGMP 
regulations) for validating manufacturing processes. The dependence on intensive in-process 
and finished product testing can be reduced. However, in-process and finished product testing 
still play an important role in assuring that products meet specifications. A properly validated 
and controlled process will yield little scrap or rework, resulting in increased outputs. Consistent 
conformance to specifications is likely to result in fewer complaints and recalls. Also, when 
needed, the validation files contain data to support improvements in the process or the 
development of the next generation of the process (FDA, 2009).  
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2.4. Manufacturing Process Validation over Products Lifecycle 
 
Several factors, such as manufacturing equipment, raw materials, and processing 
conditions, are likely to impact product quality. Assurance of product quality is derived from 
product and process design, adequate control of input process parameters, and testing of in-
process and finished product samples. Each step of the manufacturing process must be 
controlled to maximize the probability that the finished product meets all quality and process 
requirements.  
A Process Validation is the collection and evaluation of data, from the process designed 
stage and continuing through commercial production, which ensure that the manufacturing 
process including equipment, building, personnel and materials is capable of achieving the 
intended results on a consistent and continuous basis (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011). In all stages of the product 
lifecycle, good project management and good archiving that capture scientific knowledge will 
make the process validation program of a Pharmaceutical industry more effective and efficient. 
These practices should ensure uniform collection and assessment of information about the 
process and enhance the accessibility of such information later in the product lifecycle. Broadly 
speaking, any study that supports process-parameters ranges in the license application and/or 
master batch record is considered part of the process lifecycle validation study such as 
development, characterization, and process performance qualification (PPQ)(Process Lifecycle 
Validation: Applying Risk Management, 2013). This Guidance for Process Validation with this 
new approach (Guidance for Industry - Process Validation: General Principles and Practices, 
January 2011) describes process validation activities in three stages, that occur in more than 
one stage at the same time: 
 
 
1. Process Design: The commercial manufacturing process is defined during this 
stage based on knowledge gained through development and scale-up activities. 
The outcome is the design of a process suitable for routine manufacture that 
will consistently deliver product that meets its critical quality attributes. 
 
2. Process Qualification: The process design is evaluated to determine if the 
process is capable of reproducible commercial manufacturing. 
 
3. Continued Process Verification (CPV): Continual assurance that the process 
remains in a state of control (the validated state) during commercial 
manufacture. 
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Figure 5: Process Validation – Life Cycle Approach 
(FDA Process Validation Guidance and the PDA Process Validation Interest Group, March 14, 2012) 
 
Process validation studies are expected to enhance process understanding/ knowledge 
throughout the product lifecycle. The manufactures are requested to follow ongoing programs to 
collect and analyze product and process data to evaluate the state of control of the process. 
With the issuance of the FDA guidance document on process-validation (Guidance for Industry - 
Process Validation: General Principles and Practices, January 2011), process validation 
activities should be viewed using a product lifecycle approach. 
 
2.4.1. STAGE 1: Process Design  
 
For pharmaceutical products under development, there are some basic rules that must be 
followed during transformation of an idea into a product to ensure patient protection: the product 
must be safe, product should be effective, and the product must meet a patient`s need or want. 
  
PART 1 – Building and Capturing Product and Process Knowledge/ Understanding 
Good process design and development should anticipate significant sources of variability 
and establish appropriate detection, control, and/or mitigation strategies, as well as appropriate 
alert and action limits (Guidance for Industry - Process Validation: General Principles and 
Practices, January 2011). Product realization can be defined as: “The sum total of all the 
processes that are used to bring a product into being” and involves starting with raw materials 
and working them into defined finish product (Process Lifecycle Validation: Applying Risk 
Management, 2013).  
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Figure 6: A Process design approach incorporating Quality by Design 
(Quality by Design, 2012) 
 
 
The aim of this stage is to design a process (e.g., process development, scale-up, and 
characterization) suitable for routine commercial manufacturing that can consistently deliver a 
product within specifications. In order to assure Product validation Lifecycle Quality by Design is 
the start concept of Process Design. Design space can illustrate understanding of parameter 
interactions and provides manufacturing flexibility. A good planning Process Development 
Project accomplishes the following tasks: 
 Understand the process; 
• Assessment of CQAs; 
• Design Space (and Proven Acceptable Range); 
• Analysis of Critical Control Parameters (CCP) (or also called CPP) in order 
to ensure that the process will be under control; 
 Develop a control Plan; 
 Scale-up; 
 Process Validation. 
Very recently (in last October 2013) FDA and EMA announced their reflection on the topic 
of Design Space Verification. Design space verification is a demonstration that the proposed 
combination of process parameters and materials attributes is capable of manufacturing a 
quality product at commercial scale. Thus, Design Space Verification should occur over the 
product lifecycle as initial design space is normally developed based on experiments conducted 
at laboratory or pilot scale and often occurs solely at or near the target operating ranges. 
However, movements from one area to another area (e.g. scale-up) within the design space but 
re-establishing NOR in an unverified area, may pose higher risks or unknown risks due to 
potential models and assumptions (Figure 6). It is essential that these risks are understood and 
evaluate utilizing an appropriate control strategy, including but not restricted to the controls 
submitted in the dossier. 
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At this stage the activities and attributes that will be reflected in Master Batch Records and 
control records are designed. Product development activities provide key characteristics: 
o Quality target product profile (Guidance for Industry - Q8 Pharmaceutical 
Development, May 2006); 
o Intended dosage form; 
o Route of administration; 
o Expected drug product quality attributes based on knowledge management 
and risk management (Pharmaceutical Quality System - ICH Q10, 2011); 
o General manufacturing pathway. 
 
The basis for design of a pharmaceutical product is the quality target product profile 
(QTPP) defined as: “A prospective summary of the quality characteristics of a drug product that 
ideally will be achieved to ensure the desired quality, taking into account safety and efficacy of 
the drug product”. The QTPP forms the basis of design for development of the product and the 
process and should be one of the first documents to be placed in a product specification or 
design-history file (Process Lifecycle Validation: Applying Risk Management, 2013). 
Designing an efficient process with an effective process control approach is dependent on 
process knowledge and understanding obtained. Therefore, product and process 
characterization activities are crucial: 
– Design of Experiments (DOE) (Design space / Design Control, revealing multivariate 
interactions, relationships between CPPs and inputs, and CQAs and outputs). The 
results of DOE studies can provide an explanation for establishing ranges of incoming 
component quality, equipment parameters, and in-process material quality attributes. 
 
Figure 7: A quality by design approach to product and process development 
(Quality by design study: An integrated multivariate approach to drug product and process development, 2009) 
 
– Risk Assessments are used to screen potential variables for DOE studies to minimize 
the total number of experiments conducted while maximizing knowledge gained (see 
Section 2.5.1 - Risk Assessment). Risk-based approaches could be used to determine 
study type (e.g., generic or product specific), number of experiments, and scale. Risk-
based study design shows how to incorporate prior knowledge and potential product 
quality risks in deciding process parameters (and identifying CPPs).  
 
Define QTPP 
Identify CQA`s 
CPP`s 
Establish 
Design Space 
Develop 
Control 
Strategy 
Continual 
improvement 
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– Lab or pilot scale experiments assist in evaluation of certain conditions and prediction 
of performance of the commercial process. 
 
– Computer modelling of certain unit operations or dynamics can provide process 
understanding and help avoiding problems at commercial scale. 
 
 
The functionality and limitations of industrial manufacturing equipment should be 
considered in the process design, as well as predicted contributions to variability posed by 
different raw-materials lots, production operators, environmental conditions, and measurement 
systems in the production setting. It is crucial that activities and studies resulting in process 
understanding be reported. This information is useful during process qualification and continued 
process verification stages, including when the design is revised or the strategy for control is 
improved or changed (Guidance for Industry - Process Validation: General Principles and 
Practices, January 2011). The process is finalized prior to Process Validation batches at 
commercial scale. 
 
PART 2 – Establish Process Control Strategy 
FDA expects controls to include both examination materials quality and equipment 
monitoring. Particular attention is required to control the process through operational limits and 
in-process monitoring is essential in two scenarios:  
 
1. When the product attribute is no measurable due to limitations of sampling or 
detectability (e.g., microbial contamination), or 
2. When intermediates and products cannot be highly characterized and well-defined 
quality attributes cannot be identified. 
 
Process controls address variability to assure quality of the product. Controls can consist of 
material analyses and equipment monitoring at specific processing points Strategies for 
Process can be designed in different ways (See Section 2.6 - Products’ risk framework as part 
of Manufacturing Process Validation): 
 
o Reduce input variation; 
o Adjust for input variation during manufacturing;  
o Combination of both. 
Process Analytical Technology (PAT) is an advanced control strategy that can include 
timely analyses and control loops to adjust the processing conditions so that the output remains 
constant. 
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2.4.1.1. Technology Transfer – Lifecycle stage goal  
The purpose of technology-transfer activities is to transfer product and process knowledge 
between development and manufacturing and within or between manufacturing sites to achieve 
product realization. The transfer must demonstrate comparability of the product and process 
between the donor and recipient sites. This knowledge forms the basis for the manufacturing 
process, control strategy, process validation approach and ongoing continual improvement 
(Pharmaceutical Quality System - ICH Q10, 2011). 
There may be multiple quality risk assessments associated with a technology transfer (e.g., 
risk assessments for process changes, facility and equipment changes, method transfer, and 
multiproduct operations). It is important, therefore, that Quality Risk Management (QRM) 
activities are adequately planned and documented. This risk assessment should be performed 
during the introduction of a new product to assess and review any potential cross-contamination 
or non-routine risks of mix-up between existing products at the facility and the new product. 
 
 
2.4.2. STAGE 2: Process Qualification 
 
PART 1 – Utility and Equipment Qualification 
 
During this stage it is demonstrated that utilities (Figure 8) and equipment are suitable for 
their intended use and perform their work properly. The following activities necessarily precede 
manufacturing products at the commercial scale: 
- Installation Qualification (IQ); 
- Operational Qualification (OQ); 
- Performance Qualification (PQ). 
 
Figure 8: Some common utilities used in Hikma plants 
(Applying Process Systems Engineering for Continuos Improvement in Pharmaceutical Production, 2013) 
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However these qualifications will not describe manufacturing processes, there are many 
other inputs associated with every unit operation. 
Equipment and supporting systems to be used for PPQ need to be qualified in accordance 
to GMPs (Guidance for Industry - Process Validation: General Principles and Practices, January 
2011).  
 
 
PART 2 – Process Performance Qualification (PPQ) 
The purpose of process performance qualification is to rigorously test the process to 
determine whether if it is capable of consistently producing an output or in-process or finished 
product which meets specifications. This stage has traditionally been known as “conformance 
runs” or “demonstration batches” or also called “process validation batches. In entering the 
process performance qualification phase of validation, it is understood that the: 
– product, primary packaging, and process specifications have been established, 
documented, and essentially proven acceptable through engineering, laboratory data, 
pilot studies or other verification methods; and 
– process and auxiliary equipment and the environment have been judged acceptable on 
the basis of installation and operation qualification studies. 
 
A manufacturer is required to successfully complete PPQ before starting commercial 
distribution of drug product (Guidance for Industry - Process Validation: General Principles and 
Practices, January 2011). 
The approach to PPQ should be based on: 
 
1) Overall product and process understanding 
Data should be analyzed to determine the normal range of variation for the process output. 
Knowing the normal variation of the output is crucial to determine whether if a process is 
operating in a state of control and if it is capable of consistently producing the specified output. 
 
2) Demonstration of control / assess products risk framework 
Process and product data should also be analyzed to identify any variation due to 
controllable causes. Depending on the nature of the process and its sensitivity, controllable 
causes of variation may include: 
 Temperature; 
 Presence of oxygen; 
 Light; 
 Humidity; 
 Environmental contaminants; 
 Inadequate employee training; and others. 
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The risk associated to causes of variation should be evaluated and appropriate measures 
should be taken to eliminate or control these controllable causes of variation. For example, 
extreme variations in temperature can be eliminated by installing heating and cooling system. 
Operators training can be improved and conducted more frequently and employees can be 
monitored more closely to assure that they are properly performing the process. Eliminating 
controllable causes of variation will reduce variation in the process output and result in a higher 
degree of assurance that the output will consistently meet specifications (FDA, 2009). 
After routine production begins, data derived from monitoring the process and output 
product can be analyzed for variation and compared to the normal range of variation. Such 
analyses can detect when the process output is shifting so that corrections can be made before 
(Section 2.4.3 - Stage 3: Continued Process Verification (CPV)), or soon after, nonconforming 
product is produced. 
 
3) Use of objective measures (statistics) to provide assurance of control 
Successful PPQ is reflected by the level of robustness of the manufacturing formula, 
process recipe, and standard operating procedures (SOPs). This robustness can be given by 
statistical confidence. On the other hand statistical tools can support and facilitate quality risk 
management. They can provide effective data assessment, aid in determining the significance 
of the data set, and facilitate more reliable decision making (Guidance for Industry - Q9 Quality 
Risk Management, June 2006). For e.g. robustness of contamination controls that prevent 
presence of bioburden, endotoxin, or foreign contaminants in the aseptic process streams must 
be demonstrated in PPQ batches. This demonstration is accomplished through a combination of 
process controls such as raw material specifications and testing, equipment cleaning, and 
sanitization, facility/environmental requirements and controls, operational controls, and in-
process monitoring during the production of the drug product. Regulators consider aseptic 
processing operations, such as sterile sampling, filtration, filling and lyophilization, to be high-
risk processes. 
 
 
4) Effects of scale understanding 
 
Data must exist to demonstrate that commercial-scale manufacturing process is 
reproducible, can be maintained within established parameters, and consistently produces 
product that meets product specifications.  
However, it is not typically necessary to explore the entire operating range at commercial 
scale if assurance can be provided by process design data. Previous credible experience with 
sufficiently similar products and processes can also be supportive.  
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In most of the cases, PPQ will have a higher level of sampling, additional testing, and 
greater scrutiny of process performance than during routine commercial production (see Figure 
9). The level of scrutiny, testing, and sampling should continue through the process verification 
stage (Section 2.4.3 - Stage 3: Continued Process Verification (CPV)) as appropriate, to 
establish levels and frequency of routine sampling and monitoring for the particular product and 
process.  
 
 
How many Validation Runs is State-of-Art today? 
 
For many years the "magical three validation runs" completed successfully were regarded 
as state-of-the-art in order to be able to define a process as validated. But already in the PIC/S 
(Pharmaceutical inspection convention / Pharmaceutical inspection co-operation scheme - 
PIC/S, 25 September2007) on the topic qualification/ validation is stated analogously that 
theoretically the number of validation runs should be sufficient to show the normal level of 
variations and to recognize trends and to collect sufficient data for the assessment. But 
nevertheless the number three is still mentioned in this document.  
In the new Guidance on Process Validation (Guidance for Industry - Process Validation: 
General Principles and Practices, January 2011) continues with these reflections and does not 
mention a number of validation runs any more. Instead the following considerations are made: 
- For the duration of the heightened sampling and monitoring period the following should 
be considered: 
 
o Volume of production; 
o Process complexity; 
o Manufacturing Process Risk Analysis; 
o Level of process understanding; 
o Experience with similar products and processes. 
 
- More variability implies more runs (to assure that the results are meaningful and 
consistent). 
 
- More uncertainty implies more runs (to assure that the results are meaningful and 
consistent). 
 
- Range of conditions allowed in written standard operating procedures. 
Historically, also there has been limited application of risk assessment in defining the 
number of batches and studies. Under the concept of using a science- and risk-based 
approach, when selecting the number of batches in the PPQ, appropriate use of scientific data, 
Chapter 2   LITERATURE OVERVIEW 
18 
 
risk management, and statistical tools should be considered. Batches should not be selected 
without taking these considerations into account (Process Lifecycle Validation: Applying Risk 
Management, 2013).  
Nevertheless, it seems that the one time rule of thumb for running three verification 
batches is no longer so straightforward; it depends on the level of product and process 
knowledge the company has acquired from development studies.   
A manufacturing process that uses PAT
2
 may follow a different PPQ approach. Stage 1 
and Stage 2 of this Lifecycle Process Validation approach should focus on the measurement 
system and control loop for the measured attribute. Regardless, the objective of validating any 
manufacturing process is the same: establish scientific evidence that the process is 
reproducible and will consistently deliver quality products. 
 
 
Product Performance Qualification 
The purpose of product performance qualification is to demonstrate that the process has 
not adversely affected the finished product and that the product meets its predetermined 
specifications and quality attributes. Product performance qualification and design validation of 
initial finished product are directly related. According to the design control requirements, design 
validation shall be performed under defined operating conditions on initial production units, 
engineering batches, or Process Validation batches. Products used for design validation should 
be manufactured using the same production equipment, methods and procedures in order to 
challenge commercial production. Otherwise, the product used for design validation may not be 
representative of production units and cannot be used as evidence that the manufacturing 
process will produce a product that meets pre-determined specifications and quality attributes. 
 
 
PPQ Documentation 
Any planned, documented study that adds process knowledge and supports product 
licensure is considered part of process validation. Risk-based approaches could be used to 
determine study type (e.g. generic or product specific), number of tests and scale (Process 
Lifecycle Validation: Applying Risk Management, 2013). Procedures for monitoring and control 
of process parameters must be established and maintained for validated processes. A PPQ 
Protocol and subsequent PPQ Report are the main documents and the guidelines of each 
validated process.  
 
 
                                                     
2
 PAT processes are designed to measure in real time the attributes of an in-process material and then adjust the process in a timely control loop o the process 
maintains the desired quality of the output material.   
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a) PPQ Protocol 
 
Process Performance Qualification Protocol is a written plan stating how validation will 
be conducted, including test parameters, product characteristics, production equipment, and 
decision points on what constitutes acceptable test results. Thus, this plan should document a 
complete list of process validation studies required for product/ process licensure, including the 
appropriate level of effort and timing of process validation activities. Understanding challenges 
in applying risk management and common factors that may result in unsuccessful process 
validation would help to take the suitable measures to overcome them (Process Lifecycle 
Validation: Applying Risk Management, 2013). Planning for the validation must include the 
following main elements as well as any other relevant issues that must be addressed to conduct 
the validation study: 
 
 Manufacturing conditions, including operating parameters, processing limits, conditions 
to be placed on preceding processes and components inputs. 
 
o Consideration of maintenance and repairs needs;  
o Assumptions (shifts, operators, equipment, components); 
o Identification of equipment to be used in the process; 
o Identification of utilities for the process equipment and quality of the utilities. 
 
 Criteria and process performance indicators
3
 that allow a decision based on science 
and risk about the ability of the process to consistently produce quality products. 
 
o Product risk analysis – assessment process and product risk framework; 
o Process parameters and Product characteristics to be controlled and 
monitored, and methods for controlling and monitoring;  
o Statistical methods for data collection and analysis; 
o Provision for addressing deviations from expected conditions and handling of 
nonconforming data. Data cannot be excluded from further consideration in 
terms of PPQ without a documented, scientific justification. 
 
 Testing, including acceptance criteria. 
 
 Data collection and evaluation. 
 Sampling plan (intra‐ and inter‐batch quality) including sampling points, number of 
samples, and frequency of sampling for each unit operation and attribute. The 
confidence level selected is based on Risk Analysis as it relates to the particular 
                                                     
3
 Performance indicators: Measurable values used to qualify quality objectives to reflect the performance of an organization, process or system, also known 
as performance metrics in some regions(Pharmaceutical Quality System - ICH Q10, 2011). 
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attribute under examination. Sampling during this stage should be more extensive than 
is typical during routine production (see Figure 9). 
 
 
Figure 9: Scheme exemplifying Process Validation Sampling over Product Lifecycle 
 
The validation plan should also cover the installation and operation qualification of any 
equipment used in the process performance qualification, and product performance qualification 
(FDA, 2009). Proper training and motivation of personnel are prerequisites to successful 
validation. The revision and approval of the protocol by appropriate departments and the quality 
unit are necessary prior to its execution. The commercial manufacturing process and routine 
procedures must be followed during PPQ Protocol execution (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011). 
 
b) PPQ Report 
 
A report is prepared in a timely manner after the completion of PPQ runs documenting 
and assessing adherence to the written PPQ Protocol (Figure 10). This report is supposed 
to: 
 
 Discuss and cross-reference all aspects of the protocol; 
 Summarize data and results from PPQ runs; 
 Evaluate any unexpected observations and additional data not specified in the 
PPQ protocol;  
 Summarize and discuss all manufacturing non-conformities such as deviations, 
aberrant test results, or other information that has bearing on the validity of the 
process; 
 Describe in sufficient detail any corrective actions or changes that should be 
made to existing procedures and controls; 
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 Conditions that may indicate that the process or part of the process should be 
revalidated; 
 State a clear conclusion regarding state of control; 
 Include all related department and quality unit in the review and approval. 
 
Release of PPQ Batches 
 
Normally, completion of all PPQ batches and approval of PPQ reports is required for 
commercial distribution of a product and a high degree of assurance in the process achieved. 
Though, under special circumstances, concurrent release
4
 of PPQ batches may be acceptable: 
 
o Infrequently manufactured (orphan drugs); 
o Short half lives (shelf life); 
o Drug shortage. 
 
Figure 10: Risk-Based Validation Lifecycle 
 (Risk-Based Validation and Requalification of Process & Equipment, 2009). 
 
                                                     
4 Concurrent release: Releasing for distribution a lot of finish product, manufactured following a qualification protocol, that meets the lot release criteria 
established in the Protocol, but before the entire study protocol has been executed. 
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2.4.3. Stage 3: Continued Process Verification (CPV) 
Manufacturers of legacy products can take advantage of the knowledge gained from the 
original process development and qualification work as well as manufacturing experience to 
continually improve their processes (Guidance for Industry - Process Validation: General 
Principles and Practices, January 2011). Various changes that occur during a manufacturing 
process lifetime include normal process variability over time (see Section 4.3.2 - 
Controlled Variation), changes in the manufacturing equipment that influence the process and 
control system, and process improvement. Trending of process monitoring data at established 
intervals is useful in the ongoing evaluation of the process. Statistical analysis and trending of 
the data should be applied to alert any undesirable process behavior (see Chapter 4 - 
PARAMETERS AND METHODS – Quality Risk Management Tools). Where no significant 
changes have been made and process-monitoring verification confirms that slight changes have 
not impacted the system or process and maintained consistent results, there is then no need for 
repletion of PPQ runs. Certain regulatory authorities may require revalidation for a specific 
product or process. Changes to processes, raw materials, specifications, methods, procedures, 
labeling, and packaging systems must be evaluated per approved change-control procedure. 
Hence, lifecycle approach for process validation is now an expectation from regulatory agencies 
(Guidance for Industry - Process Validation: General Principles and Practices, January 2011) 
(Guideline on Process Validation, 29 March 2012). 
How is Continued Process Verification accomplished? 
 
 Consistency beyond the initial qualification batches is demonstrated through continuing 
monitoring of a subset of the original parameters evaluated. In order to accomplish it the 
following proceedings is recommended (refer to Figure 11): 
- System for detecting unplanned divergence from the process as designed; 
- Ongoing program to collect and analyze product and process data that relate to product 
quality (process trends, in‐process controls, finished product testing against 
specifications); 
- Statistical trending reviewed by trained personal (see Figure 12 and Figure 13); 
- Ongoing process monitoring of process parameters and quality attributes; 
- Annual Product Quality Reviews (PQR); 
- Executed batch records; Management review and production staff feedback 
- CAPAs; 
- Ongoing risk management; 
- Improvement initiatives through process experience; 
- Other means to detect variation (deviations / non‐conformances, out‐of‐specification 
results, out of trend results, batch records, defect complaints, adverse event reports, 
process yield variation etc.). 
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Figure 11: Quality system Hierarchy 
FDA recommends continued monitoring and sampling of process parameters and quality 
attributes at the level established during PPQ until sufficient data is available to generate 
variability estimates. These estimates can provide the basis for establishing levels and 
frequency of routine sampling and monitoring for the particular product and process. These 
activities might suggest ways to improve and optimize the process by altering some aspect of 
the process or product, such as the operating conditions (ranges and set-points), process 
controls, component, or in-process material characteristics. 
Sampling frequency can then be adjusted to a statistically appropriate and representative 
level. The monitoring strategy should be documented (e.g., parameter monitoring, and statistical 
process control) (Guidance for Industry - Process Validation: General Principles and Practices, 
January 2011).  
In contrast, a science- and risk-based approach applied through the process lifecycle is 
more effective and robust. The evaluation of process changes can determine the significance of 
the change and define the necessary supporting validation study requirements and any 
potential requirements for regulatory reporting. An evaluation of the potential impact of a change 
on that unit operation, as well as potentially impacted steps downstream of that unit operation, 
is required to determine the scope and significance of required verification studies. It is 
important to determine the significance of a process change and define the review schedule of a 
validated process (Process Lifecycle Validation: Applying Risk Management, 2013). 
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2.4.3.1 Applying New Guidance to Old Products 
 
 
The ambition of the third validation stage is continual assurance that the process remains 
in a state of control (the validated state) during commercial manufacture. A system or systems 
for detecting unplanned departures from the process as designed is essential to accomplish this 
goal. In Theory manufacturing experience should yield increased knowledge and process 
improvements, and a lack of process improvements indicates lack of process understanding 
and failure to learn (implement learning). 
In practice, if it is not broken, it is not fixed! Before, the manufacturers were reluctant to 
change a process once validated and to look backward at released lots. Analysis, trending, and 
assessing variability are the basis for the identification of critical process parameter (CPPs) and 
critical material attributes (CMAs) for specific unit operation or process step needs to be 
evaluated according to 2011 FDA Process validation Guidance. Not only deviations or OOS 
results are the impulse needed for the change. A proactive search for controlling CPPs and 
CMAs is the new challenge requested from authorities. The initial selection of parameters or 
evaluation in process studies should include scientific rational and the use of risk-based 
approaches where relevant. The highest risk (i.e. parameters with the greatest likelihood of 
product impact) should be evaluated first.  
 
2.4.3.2 Establishing a CPV Program 
 
 
Several possible methods of organizing CPV are available, one of which is assembling a 
multi‐disciplinary team. For this purpose, the management appoints a person responsible for 
process validation (process validation officer), who must have adequate training in statistical 
process control techniques develop the data collection plan and statistical methods and 
procedures used in measuring and evaluating process stability and capability.  
A validation program (SOP or Validation Plan), which determines the scope of its work, its 
priorities, the time-schedule, the resources needed, etc. should be approved across all 
departments and functions concerned. The basis of the program should also be well established 
concerning data collection and recording, plotting, analyses, response to out-of-control (OOC) 
results, reporting frequency and pathway for improvements.  
After CPV program approval small steps can be given for assess normality of data and 
establish control limits data points needed, once again the first evaluated should be the highest 
risk. The data can be obtained, either retrospectively or prospectively, plot data within 
specification limits, look for obvious issues as trends (Figure 12), visual mean value offset from 
target or specification centerline or bi‐modal results (Figure 13) or insufficient resolution (pH 
only recorded to 0.1 unit), or other specificities in process outputs. 
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Figure 12: Challenges: Artefacts are found in data review – Trend. 
 
Figure 13: Challenges: Artefacts are found in data review – Bimodal results. 
 
2.5. Connection of Process Validation, Quality System and 
Quality Risk Management 
 
Before any batch is commercialized, the manufacturer should have gained a high degree of 
assurance in the performance of the manufacturing process such that it will consistently 
produce drug products meeting those attributes relating to identity, strength, quality, purity, and 
potency (CQAs). The assurance should be obtained from objective information and data from 
laboratory, pilot, and/or commercial scale studies. Information and data should demonstrate that 
the commercial manufacturing process is capable of consistently producing acceptable quality 
products within commercial manufacturing conditions (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011).  
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Figure 14: Diagram of the ICH Q10 Pharmaceutical Quality System Model 
 (Pharmaceutical Quality System - ICH Q10, 2011) 
 
The Pharmaceutical Quality System (PQS) defines process validation as establishing by 
objective evidence that a process consistently produces a result or product meeting its 
predetermined specifications. As described earlier, a successful process validation contributes 
significantly to assuring drug quality. The basic principle of quality assurance is that a drug 
should be produced that is appropriate for its intended use. This principle incorporates the 
understanding that the following conditions exist:  
 QUALITY, SAFETY and EFFICACY are built into the product. 
 Quality cannot be adequately assured merely by in-process and finish-product 
inspection or testing. 
 Each step of a manufacturing process is controlled to assure that the finish product 
meets all quality attributes including all specifications (Guidance for Industry - 
Process Validation: General Principles and Practices, January 2011). 
PQS continual improvement approach (Table 1) compiles essential elements as, 
monitoring of process performance, CAPA, Change management; supportive elements to 
identify and implement appropriate product quality improvements, variability reduction, 
innovations and pharmaceutical quality system enhancements, thereby increasing the ability to 
fulfil quality needs consistently (Pharmaceutical Quality System - ICH Q10, 2011).  
 
 
The benefits of QRM include early detection of risks, providing a broader reach than 
traditional Quality Assurance and Quality Control methods can obtain and performing deeper 
insights with regards to quality risks and compliance around clinical development processes 
within an organization. The core objectives for effective quality risk management will help to 
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ensure patient safety and data integrity. Both EMA and FDA have been active in fostering these 
concepts.  
 
There is a variety of potential uses for quality risk management tools and principles in the  
injectables manufacturing (Integrated Quality Management, Regulatory Operations, 
Development, Facilities, Equipment and Utilities, Materials Management, Production, 
Laboratory Control, Stability Studies, Packaging and Labelling). The focus of the QRM tools in 
the next chapters will be emphasizing the use for manufacturing process validation of 
Injectables. 
 
Quality risk management (QRM) is integral to an effective PQS, as it is the cornerstone of 
any science- and risk-based approach for modern drug development and manufacturing 
(Brindle, et al., 2012). It can provide a proactive approach identifying and prioritising, 
scientifically evaluating and controlling potential risks to quality. It facilitates continual 
improvement of process performance and product quality throughout the product lifecycle. QRM 
help setting meaningful specifications and CPPs to ensure product CQAs are met 
(Pharmaceutical Quality System - ICH Q10, 2011). 
QRM is a systematic process for the assessment, control, communication and review of 
risks to the quality of the drug product across the product lifecycle. A model for QRM according 
to Q9 guidance is outlined in the diagram (Figure 15).  
 
Figure 15: Overview of a typical quality management process 
 (Guidance for Industry - Q9 Quality Risk Management, June 2006). 
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2.5.1. Risk Assessment 
 
An appropriate risk assessment can minimize the process risk. The risk assessment has to 
be part of a quality risk management system (Figure 15), which should include experts from 
multiple disciplines to ask the following questions: 
- What can go wrong in the process? 
- How frequently occurs? 
- What are the consequences if this process goes wrong? 
 
The first step of risk assessment construction is RISK IDENTIFICATION. This first task is 
identifying the hazards (e.g. illustrated in Figure 16). Essentially, identifying the hazards 
answers the questions, “What can go wrong?”; “What can cause the problems?”. This is a 
brainstorming activity as important part of this thesis. This activity should generate many known 
and potential failure modes. The goal is to make this list as exhaustive as possible. Since 
identifying all potential failures can be an enormous task when considering an entire 
manufacturing process, the process map generated during the initiation phase of the risk 
management process is a valuable tool to generate the logical breaks that organize and focus 
the brainstorming (Validation & Complience: Using Risk Analysis in Process Validation, 2007). 
 
Figure 16: Sterility as CQA of an injectable product and sources of variability that should be controlled.    
 
The next step in the risk assessment phase is risk analysis. RISK ANALYSIS involves 
using the actual risk assessment tool. The qualitative or quantitative estimation of severity or the 
consequence, and the likelihood and the ability to detect the failure, are determined during the 
risk analysis (Guidance for Industry - Q9 Quality Risk Management, June 2006). At this stage, 
for each identified risk the probability of occurrence (O), the Severity of the risk (S) and 
Detectability (D).  
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The final step in the risk assessment is the RISK EVALUATION. The risk evaluation is the 
gap analysis of the calculated risk relative to the acceptable level of risk (the action threshold). 
At this point, the risk assessment phase ends.  
The risk management process would continue through the steps of risk control, risk review 
and communication (Figure 15). This implies that over the course of the product`s lifecycle, the 
risk assessment is reviewed. This review includes adjustments to regulatory requirements or to 
additional information related to the new process. 
 
2.5.2. Risk Control 
 
Risk control includes decision making to reduce and/or accept risks. The purpose of risk 
control is to reduce the risk to an acceptable level and increase detectability. The efforts used to 
control the potential risk control should be proportional to the significance risk level(Guidance 
for Industry - Q9 Quality Risk Management, June 2006).  
 
Risk control might focus on the following questions: 
• Is the risk above an acceptable level? 
• What can be done to reduce or eliminate risks? 
• What is the appropriate balance among benefits, risks and resources? 
• Are new risks introduced as a result of the identified risks being controlled? 
Risk reduction focuses on processes for mitigation or avoidance of quality risk when it 
exceeds a specified (acceptable) level (see Figure 15). Risk reduction might include actions 
taken to mitigate the severity and probability of damage. Processes that improve the 
detectability of hazard and quality risks might also be used as part of a risk control approach. 
The implementation of risk reduction measures can introduce new risks into the system or 
increase the significance of other existing risks. Hence, it might be appropriate to revisit the risk 
assessment to identify and evaluate any possible change in risk after implementing a risk 
reduction process. 
 
Risk acceptance is a decision to accept risk (decided case by case assessment). Risk 
acceptance can be a formal decision to accept the minor risk or it can be a passive decision in 
which minor risks are not specified. For some types of harms, even the best quality risk 
management practices might not entirely eliminate risk (e.g. illustrated in green bar in Figure 
17). In these circumstances, it might be necessary an appropriate quality risk management 
support and that quality risk is reduced to a specified (acceptable) level. 
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Figure 17: Aseptic process using a risk-based approach - contamination control.    
 
2.5.3. Risk Review 
 
Address the need to revisit the risk assessment to take into account any new information/ 
experience (Quality Risk Management - The Pharmaceutical Experience, 2011): 
 Determine an appropriate frequency 
 Purpose – what items will be reviewed 
 
2.5.4. Risk Communication 
 
A product production is efficiently controlled when the information is spread across all 
departments involved: 
 Communicating information with the key groups; 
 Communicating information with stakeholders throughout; 
 Understanding our risks and conveying them to others (Quality Risk Management - The 
Pharmaceutical Experience, 2011). 
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Figure 18: Systems of a Quality Risk Management 
The information obtained from the risk analysis will only be useful if the input is appropriate. 
The results from the risk assessment often dictate the number of unit operation steps needed to 
reduce specific risks to acceptable levels.  
 
2.6. Products’ risk framework as part of Manufacturing Process 
Validation 
 
A successful validation program depends upon information and knowledge from product 
and process development that pharmaceutical manufactures hold. This knowledge and 
understanding is the basis for establishing an approach to control of the manufacturing process 
that result in products with the desired quality attributes (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011). Validation is therefore essential as 
it ensure the production of a safe product that minimizes the risk to patients. Risk analysis in 
process validation promises to minimize process risk. Risk-assessment tools help to define the 
process and identify crucial areas and/or steps in that process, areas of risk and/ or hazard, and 
critical control points (Jain, et al., 2011).  
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Figure 19: Schema for Identification and Control of variations in manufacturing process and product quality 
 (Guidance for Industry - Process Validation: General Principles and Practices, January 2011) 
 
The manufacturer should judge the degree of quality assurance on its own manufacturing 
process to justify commercial distribution of the product. Qualification efforts in addition to 
manufacturing process understanding and associated variations controlled will lead to adequate 
assurance of quality (Figure 19). After process established and confirmed, manufacturers must 
maintain the process in a state of control over the life of the process, even as materials, 
equipment, production environment, personnel, and manufacturing procedures change.  
Summing up, QRM can be part of Validation to: 
 
- Identify the scope and extent of verification, qualification, and validation activities (e.g. 
analytical methods, processes, equipment, and cleaning methods); 
- Determine the extent for follow-up activities (e.g., sampling, monitoring, and re-
validation); 
- Distinguish between critical and noncritical process steps to facilitate design of a 
validation study. 
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Risk-Based Validation as part of a Robust Process 
Robustness is the ability of a process to consistently produce the same product while 
remaining unaffected by small variations in the process. It is possible to have a repeatable 
process and not have a robustness process, but it is unlikely to have a robust process that is 
not repeatable.  
One approach to evaluating robustness of a process is to evaluate critical process steps, 
critical analyses and critical product parameters (Figure 16). This evaluation is considered 
“most appropriate challenge” of the parameter limits. Another (more common) approach is to 
obtain information on challenge conditions during process development followed by PPQ.  
The ranges of the critical process parameters and the controls must be defined. They may 
be defined either during process development or during process development. 
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Chapter 3 INJECTABLE PRODUCTS OVERVIEW 
 
Parenteral medicines are prepared scrupulously by methods designed to ensure that they 
meet pharmacopeial requirements of sterility, pyrogens/ endotoxins, particulate matter and 
other contaminants. Parental preparations (solutions, emulsions, or suspensions) may contain 
one or more active ingredients, packaged in either single-dose or multi-dose containers. 
Parental preparations are intended for injection through the skin or other external boundary 
tissue, rather than through the alimentary canal, so that the active substances they can contain 
are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. An 
injection is a preparation intended for parenteral administration and/or for constituting or diluting 
a parental article prior to administration (The United States Pharmacopeia, 2013). 
 
3.1 Nomenclature and definitions 
 
The following nomenclature pertains to five general types of preparations, all of which are 
suitable for, and intended for, parental administration. They may contain buffers, preservatives, 
or other added substances (The United States Pharmacopeia, 2013). 
1. [DRUG] Injection – Liquid preparations that are drug substances or solutions theoref.  
2. [DRUG] for Injection – Dry solids that, upon the addition of suitable vehicles, yield 
solutions conforming in all respects to the requirements for Injections. 
3. [DRUG] Injectable Emulsion – Liquid preparations of drug substances dissolved or 
dispersed in a suitable liquid medium. 
4. [DRUG] Injectable Suspension – Liquid preparations of solid suspended in a suitable 
liquid medium.  
5. [DRUG] for Injectable Suspension – Dry solids that, upon the addition of suitable 
vehicles, yield preparations conforming in all respects to the requirements for Injectable 
Suspensions.  
 
There are four main forms of parenteral preparations: injections, intravenous infusions 
(large volume parenterals), powders for injections, and implants. Certain injections and 
intravenous infusions may be presented in the form of sterile concentrated solutions, which 
must be suitably diluted before use (World Health Organization). 
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3.2 Vehicles and Added substances 
 
The vehicles for aqueous injections meet requirements of the Pyrogen Test or the Bacterial 
Endotoxins Test, whichever is specified. Water for Injection generally is used as the vehicle, 
unless otherwise specified in the monograph. Sodium chloride may be added in amounts 
sufficient to render the resulting solution isotonic. Fixed oils used as vehicles for nonaqueous 
Injections are of vegetable origin, are odorless or nearly so, and have no odor suggesting 
rancidity (The United States Pharmacopeia, 2013). 
Parenteral preparations may contain excipients such as solvents, suspending agents, 
buffering agents, substances to make the preparation isotonic with blood, stabilizers, or 
antimicrobial preservatives. The addition of excipients should be kept to a minimum. When 
excipients are used, they should not adversely affect the stability, bioavailability, safety, or 
efficacy of the active ingredient(s), or cause toxicity or undue local irritation. There must be no 
incompatibility between any of the components of the dosage form (World Health Organization) 
and there must be no interference with therapeutic efficacy or with the responses to the 
specified assays and tests (The United States Pharmacopeia, 2013). No coloring agent may be 
added, solely for the purpose of coloring the finished preparation, to a solution intended for 
parenteral administration. A suitable substance or mixture of substances to prevent growth of 
microorganisms must be added to the preparation intended for injection that are package in 
multiple-dose containers, regardless of the method of sterilization used, unless one of the 
following: (1) there are different directions in the individual monograph; (2) the substance 
contains a radionuclide with physical half-life of less than 24 hours; and (3) the active 
ingredients are themselves antimicrobial. Such substances are used in concentrations that will 
prevent the growth of or kill microorganism in the preparations for injection. The air in the 
container may be evacuated or be displaced by a chemically inert gas. Where specified in a 
monograph, information regarding sensitivity of the article to oxygen is to be provided in the 
labelling (The United States Pharmacopeia, 2013). The containers should be equipped to 
ensure adequate protection of the contents after partial withdrawal. In order to minimize the risk 
of contamination resulting from multiple penetrations of the closure, the contents of a multi-dose 
preparation should normally not exceed 30 ml (The United States Pharmacopeia, 2013). 
 
3.3 Aseptic Manufacturing 
 
The manufacturing process should meet the requirements of Good Manufacturing Practice. 
Also system of marketing authorisations ensures that all medicinal products are assessed by a 
competent authority to ensure compliance with contemporary requirements of safety, quality 
and efficacy (European Commission, December 2010).  
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Aseptic filling is an aseptic process that requires the close coordination and complex 
interaction between personal, sterilized product, the fill/finish equipment system, clean room 
and support facilities, and sterilized filling components (Comprehensive review on aseptic 
fill/finish manufacturing as per regulatory guidelines, 2011). The quality of starting materials, the 
design and maintenance of the equipment and the method of manufacture must be such as to 
ensure the stability of the active substance and the finished product which is sterile and free of 
pyrogens and particulate matter (The United States Pharmacopeia, 2013).  
Aseptic manufacturing is used in cases, where the drug substance is instable against heat; 
hence sterilization in the final container closure system is not possible. Aseptic processing 
attracts a high level of regulatory scrutiny due to risks associated with this type of manufacturing 
and its potential adverse effect on the health care consumer (Comprehensive review on aseptic 
fill/finish manufacturing as per regulatory guidelines, 2011). From the clinical viewpoint all 
parenteral preparations must be pyrogen-free (The United States Pharmacopeia, 2013). 
With respect to parental preparation sterility, the filling manufacturing process of a bulk 
solution is aseptic (following aseptic technique) and, in this case, the solution is filtered through 
a 0.2 µm filter or lower porosity filter (and procedures validated per media fill); or the product is  
terminally sterilized. For the sterilization of parenteral preparations heating in an autoclave is the 
method of choice for aqueous preparations and should therefore be used whenever possible. 
When a parenteral preparation is liable to deterioration due to oxidation, the operation of 
filling may be performed in an atmosphere of suitable inert gas, such as nitrogen, whereby the 
air in the container is replaced by filtered (sterile) nitrogen. 
Throughout manufacturing, certain procedures should be validated and monitored by 
carrying out appropriate in-process controls. These should be designed to guarantee the 
effectiveness of each stage of production. In-process controls during production of parenteral 
preparations should include monitoring of environmental conditions (especially with respect to 
particulate and microbial contamination), bacterial endotoxins, pH and clarity of solution, 
freedom from particulate matter, and integrity of container (absence of leakage, etc.). For 
dispersions controls should also include the particle size of the dispersed phase, and for 
powders for injections the uniformity of content and mass, moisture content, and the ease of 
reconstitution. The presence of preservatives or other additives should be determined as these 
can influence the choice of assay method (World Health Organization). 
 
3.3.1  Visual inspection 
 
Inspect the solutions, reconstituted solutions, and intravenous infusions (except 
dispersions). They should be clear and free from visible particulate matter. 
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3.3.2 Containers 
 
Drug product, container, and closure are first subjected to sterilization methods separately 
and appropriately; which consists of several consecutive and necessary working steps, each of 
them contributing its part towards the aim of manufacturing an aseptic product (prevention of 
microbial contamination) (Comprehensive review on aseptic fill/finish manufacturing as per 
regulatory guidelines, 2011). Parenteral preparations are usually supplied in glass ampoules, 
bottles or vials, plastic bottles or bags, and prefilled syringes, which can be amber in the case of 
light-sensitive substances.  
Except where otherwise indicated in individual monographs, these containers should be 
made from material that is sufficiently transparent to permit the visual inspection of the contents. 
They should not adversely affect the quality of the preparation, allow diffusion of any kind into or 
across the material of the container, or yield foreign substances into the preparation (The United 
States Pharmacopeia, 2013). 
 
3.3.3 Closures 
 
Closures for parenteral preparation containers should be equipped with a firm seal to 
prevent entry of microorganisms and other contaminants while permitting the withdrawal of a 
part or the whole of the contents without removal of the closure. They should not be made of 
components that react with the contents, nor should they allow foreign substances to diffuse 
into the preparation. Plastic materials or elastomers of which the closure is composed should be 
sufficiently firm and elastic to allow the passage of a needle with the least possible shedding of 
particles. Closures for multidose containers should be sufficiently elastic to allow the puncture to 
reseal when the needle is withdrawn and protect the contents from airborne contamination. A 
tamper-evident container is fitted with a device that reveals clearly whether it has ever been 
opened. 
 
3.3.4 Labelling 
 
Every pharmaceutical preparation must comply with the labeling requirements established 
under Good Manufacturing Practice. The label should include: 
(1) the name of the pharmaceutical product; 
(2) the name(s) of the active ingredient(s); INNs should be used wherever possible; 
(3) the amount of the active ingredient(s) in a suitable dose volume and the volume in the 
container; for powder for injections: the amount of the active ingredient(s) in the container; 
(4) the batch (lot) number assigned by the manufacturer; 
(5) the expiry date and, when required, the date of manufacture; 
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(6) any special storage conditions or handling precautions that may be necessary; 
(7) directions for use, warnings, and precautions that may be necessary; and 
(8) the name and address of the manufacturer or the person responsible for placing the product 
on the market. 
 
For parenteral preparations that are solutions or dispersions, the concentration of the 
active ingredient(s) should be given in terms of mass or biological activity per volume. For 
concentrated solutions, labels should state the composition and the dilution to be carried out 
before use. 
 
3.4 Injections 
 
Injections are sterile, pyrogen-free solutions or dispersions (emulsions or suspensions) 
of one or more active ingredients in a suitable vehicle. 
 
3.4.1 Suspensions 
 
A suspension drug product is typically aqueous-based formulations that contain 
therapeutically active ingredients and can also contain additional excipients. As the other 
injectable products, an aqueous-based suspension must be sterile. The final formulation should 
be expressed in concentration (i.e., amount per unit volume or weight), as well as amount per 
container (U.S. Department of Heath and Human Services and FDA and CDER, 2002).   
The production of injectable suspensions involves a complex manufacturing process.  
Suspensions are mixtures of solids with liquids, gases with liquids, in which there is no 
dissolution but there is a dispersion of one substance in the other. Colloids are the most 
common form of a suspension, and are characterized by having a high amount of dispersed 
particles.  This particles are normally at size > 0.1 µm.  
 
Figure 20: Differences in Particle sizes between a “True solution”, a Colloidal solution” and “Suspensions”. 
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The suspensions are heterogeneous systems, in which one substance is the disperse 
phase, distributed in small units in another substance that constitute the dispersant phase or 
continues phase.  
The composition of suspension formulations may be crucial in defining the physical stability 
and the performance characteristics of the drug product. The density and suspension 
proprieties of the solid materials of the formulation and potential for agglomeration (Figure 21) 
should be considered. Therefore, this type of injectable product is very difficult to be 
manufactured and additional controls are necessary to the production process. Moreover, 
interaction of the suspended drug substance with the various internal container closure system 
components can also contribute to a non-homogeneous distribution of the drug product. This 
phenomena which may be exacerbated with time, can contribute to inconsistent particle size 
distribution and medication dose delivery.  
 
Figure 21: Suspension and the phenomenon of caking which shows that suspensions are thermodynamically instable 
systems. 
 
3.5 Intravenous infusions 
 
Intravenous infusions are sterile, pyrogen-free aqueous solutions or emulsions with water 
as continuous phase, usually prepared to be isotonic. They are intended for administration in 
large volumes (usually 100 ml or more), and should not contain any antimicrobial preservatives. 
On visual inspection, emulsions for intravenous injection should show no evidence of 
phase separation. The particle size of the dispersed phase should be controlled by the 
manufacturer. 
 
3.6 Implants 
 
Implants are solid preparations containing one or more active ingredients. They are of a 
size and shape suitable for parenteral implantation, and provide release of the active 
ingredient(s) over an extended period of time. They are presented in individual sterile 
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containers. All requirements for these specialized dosage forms are given in the individual 
monographs. 
 
3.7 Powders for injections 
 
Powders for injections are solid substances (including lyophilized products), distributed in 
their final containers and which, when shaken with the prescribed volume of the appropriate 
sterile liquid, rapidly form either clear and practically particle-free solutions or uniform 
suspensions. Powders for injections, after dissolution or suspension, comply with the 
requirements for injections or intravenous infusions, as appropriate. 
 
Uniformity of mass 
Powders for injections (single-dose use) comply with the test for uniformity of mass for 
single-dose preparations, unless otherwise specified in the individual monograph. 
 
Uniformity of content 
A requirement for compliance with the test for Uniformity of content for single-dose 
preparations is specified in certain individual monographs where the active ingredient is less 
than 40 mg. In such cases, compliance with the test for Uniformity of mass for single-dose 
preparations may not be required. 
 
 
3.7.1 Lyophilization 
  
Lyophilization or freeze drying is a process in which water is removed from a liquid product 
after it is frozen and placed under a vacuum, allowing the ice to change directly from solid to 
vapor without passing through a liquid phase. Lyophilization is a complex pharmaceutical 
process, its success requires control of the manufacturing process and filling processes for the 
liquid formulation and appropriate control during the lyophilization process. The process 
consists of three separate, unique, and interdependent processes; such as freezing, primary 
drying (sublimation), and secondary drying (desorption) (U. S. Department of Health and 
Human Sevices, 2009). 
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The advantages of lyophilization include: 
 Enhanced stability of a dry powder; 
 Removal of water without excessive heating of the product; 
 Enhanced product stability in a dry state; 
 Rapid and easy dissolution of reconstituted product. 
  
Disadvantages of lyophilization include: 
 Increased handling and processing time; 
 Need for sterile diluent upon reconstitution; 
 Cost and complexity of equipment. 
 
 
Figure 22: Process Flow Diagram: The Lyophilization Process 
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The lyophilization process generally includes the following steps (see also Figure 22): 
  
o Dissolving the drug and excipients in a suitable solvent, generally water for injection (WFI). 
o Sterilizing the bulk solution by passing it through a 0.22 micron bacteria-retentive filter. 
o Filling into individual sterile containers and partially stoppering the containers under aseptic 
conditions. 
o Transporting the partially stoppered containers to the lyophilizer and loading into the 
chamber under aseptic conditions. 
o Freezing the solution by placing the partially stoppered containers on cooled shelves in a 
freeze-drying chamber or pre-freezing in another chamber. 
o Applying a vacuum to the chamber and heating the shelves in order to evaporate the water 
from the frozen state. 
o Complete stoppering of the vials usually by hydraulic or screw rod stoppering mechanisms 
installed in the lyophilizers. 
  
It is recognized that there is complex technology associated with the manufacture and 
control of a lyophilized pharmaceutical dosage form. Some of the important aspects of these 
operations include: the formulation of solutions; filling of vials and validation of the filling 
operation; sterilization and engineering aspects of the lyophilizer; scale-up and validation of the 
lyophilization cycle; transfer and scale-up of the process to a larger-scale lyophilizer; and testing 
of the end product. This thesis will address some of the problems associated with the 
manufacture and control of a lyophilized dosage form. 
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Chapter 4 PARAMETERS AND METHODS – Quality 
Risk Management Tools  
 
 
A successful validation program depends upon skilled interpretation of the information and 
knowledge gained from product and processes development regarding sources of variation, its 
impacts and associated risks. In agreement with that, this project aims to create a valuable risk 
tool to be used during lifecycle process validation to assess products’ risk framework and also 
to provide an overview of the most critical process parameters of Hikma Injectables processes 
manufacturing. 
Several risk Management Methods and Tools are available to support the various phases of 
the risk management process (Section 4.5 - Risk Management Tools Overview). In this thesis 
are also presented some of the most common statistical tools to be used in risk mitigation and 
process variability identification. A reliable process validation depends on the level of product 
and process knowledge the company has acquired from development studies and appropriate 
use of scientific data, risk management and statistical tools should be considered. 
An improved system for Hikma Risk Analysis through product lifecycle that can be widely 
used and risks that are associated to Injectables Process Parameters are presented in Chapter 
5 – RESULTS – Assess Products` Risk Framework). 
 
4.1 Critical Parameters 
 
On one hand the specific modifications of CPP are connected to process variability, on the 
other hand CPP impact on CQA, enable its manipulation to ensure the state of control and 
product quality. Therefore, CPPs and CMAs for each unit operation or process step are 
evaluated in process validation studies.  Screening experiments, product validation 
documentation, PQR, manufacturing productions of all types of Hikma products were used to 
determine CPPs. A risk-based approach for the identification of CPPs has been discussed for 
new products and existing products (see Section 2.4.1 - STAGE 1: Process Design). However, 
identification of CPPs is not a closed box and a continual search for new CPPs should be done 
over the product lifecycle and in parallel with product / process knowledge and experience. 
Process parameters can be divided into three groups: parameters warranting multivariate 
evaluation, parameters whose ranges could be supported by univariate studies and parameters 
that do not require new studies, but instead would employ ranges based on knowledge space or 
modular claims established from prior knowledge. For an existing product, comparing the 
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normal operating range (NOR) to the proven acceptable range (PAR) should be considered 
when performing a risk assessment of potential CPPs (Section 2.4.3.1 - Applying New 
Guidance to Old Products). For a new manufacturing processes that are expected to 
consistently deliver the desired product quality, PAR should be wider compared to NOR (Figure 
24). Some of the steps of drug product manufacturing are notoriously more difficult than others 
(Process Lifecycle Validation: Applying Risk Management, 2013).  
 
 
Figure 23: Process development Parameters – PAR (Proven Acceptable Range) and CpK (Process Capability Factor) 
– understanding of the process 
(Deeks, 2006). 
 
Figure 24: Process development Parameter – CpK (Process Capability Factor) – Controlled and Uncontrolled Process. 
(Deeks, 2006). 
 
4.2 Identifying Process Variation 
 
Typical sources of injectable products variability may include process equipment 
capabilities and calibration limits, testing method variability, raw materials (e.g. API and 
excipient variability between lots and suppliers), human factors for non-automated processes, 
sampling variability, and environmental factors within plant facility. A Cause and Effect Diagram 
(Figure 25) can help the initial stages of variation identification and its relationship with process 
response. 
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Figure 25: General Concept for Fishbone (Ishikawa) diagram (or Cause and Effect Diagram). 
 
When a process is stable and in state of control, it displays common cause variation, 
variation that is inherent to the process. A process is in state of control when based on past 
experience it can be predicted how the process will vary (within limits) in the future. If the 
process is unstable, the process displays special cause variation, non-random variation from 
external factors. Here, control charts are simple, robust tools for understanding process 
variability. 
 
4.2.1 The Four Process States 
 
Processes fall into one of four states: 1) the ideal, 2) the threshold, 3) the brink of chaos 
and 4) the state of chaos (Figure 26). 
When a process operates in the ideal state, that process is in statistical control and 
produces 100 percent conformance. This process has proven stability and target performance 
over time. This process is predictable and its output meets customer expectations. 
A process that is in the threshold state is characterized by being in statistical control but 
still producing the occasional nonconformance. This type of process will produce a constant 
level of nonconformances and exhibits low capability. Although predictable, this process does 
not consistently meet customer needs. 
The brink of chaos state reflects a process that is not in statistical control, but also is not 
producing defects. In other words, the process is unpredictable, but the outputs of the process 
still meet customer requirements. The lack of defects leads to a false sense of security; 
however, as such a process can produce nonconformances at any moment. It is only a matter 
of time. 
The fourth process state is the state of chaos. Here, the process is not in statistical control 
and produces unpredictable levels of nonconformance.  
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Figure 26: Four Process States 
 
Every process falls into one of these states at any given time, but will not remain in that 
state. All processes will migrate toward the state of chaos (Figure 27). Companies typically 
begin some type of improvement effort when a process reaches the state of chaos (although 
arguably they would be better served to initiate improvement plans at the brink of chaos or 
threshold state). Control charts are robust and effective tools to use as part of the strategy used 
to detect this natural process degradation (Berardinelli, 2013). 
 
Figure 27: Natural Process Degradation 
 
 
4.3 Control Charts 
 
The most common risk assessment tools are check lists, which are a useful tool to help in 
hazards identification. There are other simple techniques used to structure risk management by 
organizing data and facilitating decision-making are flow-charts, check sheets, process-mapping 
and cause-effect diagrams. 
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Also, supporting risk tools are statistical tools as Control charts (c-charts, p-charts, np-charts, 
u-charts), Histograms and Pareto charts. 
The most common application of control charts is to improve processes, as a tool to 
monitor process stability and state of control. A less common, although more powerful, use of 
control charts is as an analysis tool. The descriptions below provide an overview of the different 
types of control charts to support identification of the best chart for any monitoring situation, 
followed by a description of the method for using control charts for analysis (Berardinelli, 2013). 
 
4.3.1 Elements of a Control Chart 
 
There are three main elements of a control chart as shown in Figure 28. 
1. A control chart begins with a time series graph. 
2. A central line (X) is added as a visual reference for detecting shifts or trends – this is also 
referred to as the process location. 
3. Upper and lower control limits (UCL and LCL) are computed from available data and 
placed equidistant from the central line. This is also referred to as process dispersion. 
 
Figure 28: Elements of a Control Chart 
 
Control limits (CLs) ensure time is not wasted looking for unnecessary trouble – the goal of 
any process improvement practitioner should be to only take action when warranted. Control 
limits are calculated by: 
 
- Estimating the standard deviation, σ, of the sample data (at least 10 batches data); 
- Multiplying that number by three; 
- Adding (3 x σ to the average) for the UCL and subtracting (3 x σ from the average) for 
the LCL; 
Mathematically, the calculation of control limits looks like: 
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Because control limits are calculated from process data, they are independent of customer 
expectations or specification limits. 
Control rules take advantage of the normal curve in which 68.26 percent of all data is within 
plus or minus one standard deviation from the average, 95.44 percent of all data is within plus 
or minus two standard deviations from the average, and 99.73 percent of data will be within plus 
or minus three standard deviations from the average. As such, data should be normally 
distributed (or transformed) when using control charts, or the chart may signal an unexpectedly 
high rate of false alarms. 
 
4.3.2 Controlled Variation 
 
Controlled variation is described as a stable and consistent pattern of variation over time, 
and is associated with common causes. A process operating with controlled variation has an 
outcome that is predictable within the bounds of the control limits.  
 
 
 
Figure 29: Example of Controlled Variation 
 
4.3.3 Uncontrolled Variation 
Uncontrolled variation is characterized by variation that changes over time and is 
associated with special causes. The outcomes of this process are unpredictable; a 
manufacturer may be satisfied or unsatisfied given this unpredictability.  
 
Figure 30: Example of Uncontrolled Variation 
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It is important to emphasize that process control and process capability are two different 
things. A process should be stable and in control before process capability is assessed.  
 
 
Figure 31: Relationship of Control Chart to Normal Curve 
 
 
4.3.4 Control Charts for Continuous Data 
 
4.3.4.1 Individuals and Moving Range Chart 
The individuals and moving range (I-MR) chart is one of the most commonly used control 
charts for continuous data; it is applicable when one data point is collected at each point in time. 
The I-MR control chart is actually two charts used in tandem (Figure 32). Together they monitor 
the process average as well as process variation. With x-axes that are time based, the chart 
shows a history of the process. 
The I chart is used to detect trends and shifts in the data, and thus in the process. The 
individuals chart must have the data time-ordered; that is, the data must be entered in the 
sequence in which it was generated.  
The MR chart shows short-term variability in a process – an assessment of the stability of 
process variation. The moving range is the difference between consecutive observations. It is 
expected that the difference between consecutive points is predictable. Points outside the 
control limits indicate instability. If there are any out of control points, the special causes must 
be eliminated. 
Once the effect of any out-of-control points is removed from the MR chart, the I chart should be 
evaluated and the process should be corrected. 
 The I-MR chart is best used when: 
- The natural subgroup size is unknown. 
- The integrity of the data prevents a clear picture of a logical subgroup. 
- The data is scarce (therefore subgrouping is not yet practical). 
- The natural subgroup needing to be assessed is not yet defined. 
Chapter 4   PARAMETERS AND METHODS – Quality Risk Management Tools 
50 
 
 
Figure 32: Example of Individuals and Moving Range (I-MR) Chart 
 
Another commonly used control chart for continuous data is the Xbar and range (Xbar-R) 
chart (Figure 33). Like the I-MR chart, it is comprised of two charts used in tandem. The Xbar-R 
chart is used when you can rationally collect measurements in subgroups of between two and 
10 observations. Each subgroup is a snapshot of the process at a given point in time. The 
chart’s x-axes are time based, so that the chart shows a history of the process. For this reason, 
it is important that the data is in time-order. 
The Xbar chart is used to evaluate consistency of process averages by plotting the 
average of each subgroup. It is efficient at detecting relatively large shifts (typically plus or 
minus 1.5 σ or larger) in the process average. 
The R chart, on the other hand, plot the ranges of each subgroup. The R chart is used to 
evaluate the consistency of process variation. Look at the R chart first; if the R chart is out of 
control, then the control limits on the Xbar chart are meaningless. 
 
Figure 33: Example of Xbar and Range (Xbar-R) Chart 
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In  
Table 2 shows the formulas to calculate the control limits. Many software packages do 
these calculations without much user effort. The control limits are a function of the average 
range (Rbar). This is the technical reason why the R chart needs to be in control before further 
analysis. If the range is unstable, the control limits will be inflated, which could cause an errant 
analysis and subsequent work in the wrong area of the process. 
 
Table 2: Control Limit Calculations 
 
 
Table 3: Constants for calculation Control Limits 
Constants for Calculating Control Limits 
n (Sample Size) d2 D3 D4 
2 1.128 – 3.268 
3 1.693 – 2.574 
4 2.059 – 2.282 
5 2.326 – 2.114 
6 2.534 – 2.004 
7 2.704 0.076 1.924 
8 2.847 0.136 1.864 
9 2.970 0.184 1.816 
10 3.078 0.223 1.777 
11 3.173 0.256 1.744 
12 3.258 0.283 1.717 
13 3.336 0.307 1.693 
14 3.407 0.328 1.672 
15 3.472 0.347 1.653 
 
The I-MR and Xbar-R charts use the relationship of Rbar/d2 as the estimate for standard 
deviation. The constant, d2, is dependent on sample size. The difference between these two 
charts is simply the estimate of standard deviation. 
 
4.3.5 Control Charts for Discrete Data 
 
4.3.5.1 c-Chart 
Used when identifying the total count of defects per unit (c) that occurred during the 
sampling period, the c-chart allows the practitioner to assign each sample more than one 
defect. This chart is used when the number of samples of each sampling period is essentially 
the same. 
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Figure 34: Example of c-Chart 
 
 
4.3.5.2 u-Chart 
 
Like c-chart, the u-chart is used to track the total count of defects per unit (u) that occur 
during the sampling period and can track a sample having more than one defect. However, 
unlike a c-chart, a u-chart is used when the number of samples of each sampling period may 
vary significantly. 
 
Figure 35: Example of u-Chart 
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4.3.5.3 np-Chart 
 
Use an np-chart when identifying the total count of defective units (the unit may have one 
or more defects) with a constant sampling size. 
 
Figure 36: Example of np-Chart 
 
 
4.3.5.4 p-Chart 
Used when each unit can be considered pass or fail – no matter the number of defects – 
a p-chart shows the number of tracked failures (np) divided by the number of total units (n). 
 
Figure 37: Example of p-Chart 
 
 
Chapter 4   PARAMETERS AND METHODS – Quality Risk Management Tools 
54 
 
4.3.6 Selection of a Control Chart 
 
Although this chapter describes a plethora of control charts, there are simple questions a to 
be ask to find the appropriate chart for any given use. Figure 38 walks through these questions 
and directs the user to the appropriate chart. 
 
Figure 38: Mechanism for selection of the appropriate Control Chart 
 
A number of points may be taken into consideration when identifying the type of control 
chart to use, such as: 
- Variables control charts (those that measure variation on a continuous scale) are more 
sensitive to change than attribute control charts (those that measure variation on a 
discrete scale). 
- Variables charts are useful for processes such as measuring tool wear. 
- Use an individual chart when few measurements are available (e.g., when they are 
infrequent or are particularly costly). These charts should be used when the natural 
subgroup is not yet known. 
 
A measure of defective units is found with u- and c-charts. In a u-chart, the defects within 
the unit must be independent of one another, such as with component failures. Use a u-chart for 
continuous items, such as fabric (e.g., defects per batches of years). A c-chart is a useful 
alternative to a u-chart when there are a lot of possible defects on a unit, but there is only a 
small chance of any one defect occurring (e.g., errors in a roll of material). These charting 
proportions, p- and np-charts are useful for e.g., compliance rates or process yields. 
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4.4 Control Charts as a Tool for Analysis 
 
Subgrouping is the method for using control charts as an analysis tool. The concept of 
subgrouping is one of the most important components of the control chart method. The 
technique organizes data from the process to show the greatest similarity among the data in 
each subgroup and the greatest difference among the data in different subgroups. 
The aim of subgrouping is to include only common causes of variation within subgroups and 
to have all special causes of variation occur among subgroups. When the within-group and 
between-group variation is understood, the number of potential variables – that is, the number 
of potential sources of unacceptable variation – is reduced considerably, and where to expend 
improvement efforts can more easily be determined. 
 
4.4.1 Within-subgroup Variation 
 
For each subgroup, the within variation is represented by the range. The R chart displays 
change in the within subgroup dispersion of the process and answers the question: Is the 
variation within subgroups consistent? If the range chart is out of control, the system is not 
stable. It tells you that you need to look for the source of the instability, such as poor 
measurement repeatability. Analytically it is important because the control limits in the X chart 
are a function of R-bar. If the range chart is out of control then R-bar is inflated as are the 
control limit. This could increase the likelihood of calling between subgroup variation within 
subgroup variation and send you off working on the wrong area. 
 
Figure 39: Within Subgroup Variation 
 
Within variation is consistent when the R chart – and thus the process it represents – is in 
control. The R chart must be in control to draw the Xbar chart.  
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Figure 40: Example of R Chart 
 
4.4.2 Between Subgroup Variation 
 
Between-subgroup variation is represented by the difference in subgroup averages. 
 
 
Figure 41: Between Subgroup Variation 
 
4.4.3 Xbar Chart – other use 
 
The Xbar chart shows any changes in the average value of the process and answers the 
question: Is the variation between the averages of the subgroups more than the variation within 
the subgroup? If the Xbar chart is in control, the variation “between” is lower than the variation 
“within.” If the Xbar chart is not in control, the variation “between” is greater than the variation 
“within.”  
 
Figure 42: Xbar Chart within Variation 
 
In conclusion knowing which control chart to use in a given situation will assure accurate 
monitoring of process stability. It will eliminate erroneous results and wasted effort, focusing 
attention on the true opportunities for meaningful improvement. 
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4.5 Risk Management Tools Overview 
 
Risk tools are traditionally categorized as simple or detailed. Simple tools are often used as 
a precursor to using the detailed tools or early in development where little is known about 
processes, materials, and products. The list below (Figure 43) is not exhaustive and the output 
Simple Risk Tools are not particularly quantitative and are normally for identification or hazards 
and/ or risks only. These tools are extremely simple to use and yield results quickly. 
 
Figure 43: Risks hierarchy 
 (Brindle, et al., 2012) 
 
More detailed tools are used for comprehensive risk analysis, mitigation steps and include a 
quantitative calculation. Examples of these tools include FMEA (Failure Modes and Effects 
Analysis), FMECA (Failure Modes, Effects and Criticality Analysis), HACCP (Hazard Analysis 
and Critical Control Points) and AHP (Analytical Hierarchy Process). The use of these tools 
enables a comprehensive analysis of risk. All of these risk tools, either simple or detailed, can 
be complemented by a middle level risk tool RAMM (Risk Analysis and Mitigation Matrix) 
(Brindle, et al., 2012). RAMM aligns with ICH and FDA guidances (Q8 to Q10 and Process 
Validation); especially tracking Critical Quality Attributes (CQAs) and Critical Process 
Parameters (CPPs) in a pragmatic approach. 
 
4.5.1 Product Prioritization Matrices (PPM) 
 
A Prioritization Matrice can help decisions about what to do after key actions, criteria or 
Critical-To-Quality (CTQ) characteristics have been identified, but their relative importance 
(priority) is not known with certainty. This tool is used to prioritize items and describe them in 
terms of weighted criteria. It uses a combination of tree and matrix diagramming techniques to 
Simple Risk 
Tools 
•PPM (Product Prioritization Matrices)  
•PHA (Preliminary Hazard Analysis) 
Middle  
Layer 
•RAMM (Risk Analysis and Mitigation Matrix) 
Detailed Risk 
Tools 
•FMEA / FMECA 
•HACCP (Hazard Analysis and Critical 
Control Points) 
•AHP (Analytical Hierarchy Process) 
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do a pair-wise evaluation of items and to narrow down options to the most desired or most 
effective. 
To create a matrix, a judgment of the relative ability of each possible action comparing to 
every other identified action is performed to effectively deliver the results wanted. The 
parameter is a weighted ranking of all the possible actions considered. The finished matrix can 
help a team make an overall decision or determine the sequence in which to attack a problem 
or work toward an objective. 
Therefore this tool should be used when: 
1. The key root causes have been identified and the most critical causes have been 
narrowed down. 
2. When the issues are complex and they have strong interrelationships. 
3. There are very limited resources for improvement activities and hence the team must 
concentrate on the critical few. 
 
 
 
4.5.2 Preliminary hazard Analysis (PHA) 
 
This tool analysis is based on applying prior experience or knowledge of hazard to identify 
future hazards, hazardous situation. Also, it can be used for product, process and facility 
design. Another application is in early development of the project where there is little information 
on detail available. PHA is a semi-quantitative analysis that is performed to: identify all potential 
hazards and accidental events that may lead to an accident; rank the identified accidental 
events according to their severity, and identify required hazard controls and follow-up actions 
(Table 4) (Kirupakar, 2007).  
Table 4: Typical PHA worksheet 
System: Operating mode: Analyst/ Date: 
Product  Hazard Accidental 
event (what, 
where, when) 
Probable 
causes 
Contingencies / 
Preventive 
actions 
Probability Severity Comments 
... ... ... ... ... ... ... ... 
 
 
4.5.3 Risk Analysis and Mitigation Matrix (RAMM) 
 
The Risk Analysis and Mitigation Matrix (RAMM) was developed to be quantitative yet 
simple to use. The RAMM tool is potentially a useful compliment to the other risk tools and can 
Chapter 4   PARAMETERS AND METHODS – Quality Risk Management Tools 
59 
 
be used solely or in combination with other risk tools. The potential to use something 
quantitative, but not as complex as the detailed risk tools can potentially serve as the useful 
keystone of a risk management system as it is quantitatively yet manageable(Brindle, et al., 
2012).  
The tool can be applied in six stages as part of a risk management system: 
Stage 1 – Team and Knowledge – – Selecting the right team to be involved with RAMM 
workshop sessions. It is important that these individuals get an opportunity to “walk the process” 
so they get an understanding of what they are dealing with in terms of how the process is run on 
a daily basis.  
Stage 2 – Identifying the CQAs – Desired CQAs. 
Stage 3 – Define the Process Steps – Evaluation of process development and manufacturing 
to prepare the actual process, which would be the central point of the RAMM 
Stage 4 – Define Process and Material – Once the overall process is defined, each process 
should be broken down into process parameters (some of which would become critical process 
parameters) and other important parameters. 
Stage 5 – Create RAMM and Score it – The RAMM uses a matrix of process input factors and 
quality attributes to assess risk and impact. 
 
Table 5: CQAs and relative criticality 
Relative importance of 
CQA 
9 1 3 9 9 
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At this stage the RAMM could be sorted and filtered so that process inputs can be 
assessed by their impact on a specific response, by the interim process step, or for their overall 
impact on the entire process. Likewise, the matrix could be filtered to determine which process 
step or input factors had the greatest impact on a particular attribute. 
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Table 6: Short e.g. of process parameters with CQAs with risk scores detailed for just one process step (compounding). 
  Relative importance of 
CQA 
9 1 9 3 9 9 9 
TOTAL 
Process step Class Process Parameters or 
Material Attribute 
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Compounding Personal Equipment cleaning 1 1 1 1 9 1 9 23 
Compounding Procedure Bulk solution final volume 9 1 1 3 1 1 1 17 
Compounding Procedure pH adjustment 3 1 1 9 1 1 1 17 
Compounding Procedure Raw-materials dissolution 9 3 1 6 1 3 1 24 
 
Stage 6 – Mitigation – The key action designed should be around gaining improved process 
robustness. In order to improve this, experiments were defined. Additionally, it was indicated 
that some changes to the equipment would improve the equipment setup weaknesses. 
The RAMM can be integral part of an effective quality management system, facilitating 
implementation of the enabling concepts, knowledge management and quality risk 
management. 
 
4.5.4 Failure Mode Effects Analysis (FMEA) 
 
FMEA depends on product and process understanding. It methodically breaks down the 
analysis of complex processes into manageable steps. It provides evaluation of potential failure 
modes for processes and their likely effect on product performance. FMEA considers each 
mode of failure of every component of a system and ascertains the effects on the systems 
operation of each failure mode in turn therefore it is a systematic method of identifying and 
preventing products and process problems before they occur. This tool is further advanced with 
studying criticality of the consequences and providing clear indication of the situation.  
 
The application consists in: 
- Decision team; 
- Identification of potential Failure Modes, Consequences and Causes; 
- Classification of each failure mode – Severity, Occurrence and Detection; 
- Calculation of Parameter of Priority Risk (RPN); 
o Classification of each criterion 
o Multiplication of weights 
o RPN = Severity x Occurrence x Detection It will be obtained a number 
between 1 and 125. The higher the number, more serious the failure mode will 
be. 
Chapter 4   PARAMETERS AND METHODS – Quality Risk Management Tools 
61 
 
In this way it is possible to establish priorities of action and implement a control risk status 
associated to the critical activity.  
Some benefits of performing FMEA analysis include higher reliability, better quality, 
increased safety and its contribution towards cost saving includes decreased development time 
and non value added operations.   
 
4.5.5 Failure Mode Effects and Criticality Analysis (FMECA) 
 
It is the extension of the above FMEA tool. Extending FMEA to incorporate an investigation 
of the degree of severity of consequences, their probabilities of occurrence and their 
detectability is Failure mode, effects and criticality analysis. In FMECA, each failure mode of the 
product is identified and then evaluated for criticality. This criticality is then translated into a risk, 
and then translated into a risk, and if this level of risk is not acceptable, corrective action must 
be taken. This can be utilized for failure and risk associated with manufacturing processes. The 
tool can also be used to establish and optimize maintenance plans for repairable systems 
and/or contribute to control plans and other quality assurance procedures. In addition, an FMEA 
or FMECA is often required to comply with safety and quality requirements, such as ISO 9001, 
Six Sigma, FDA Good Manufacturing Practices (GMPs).  
 
4.5.6 Analytical Hierarchy Process (AHP) 
 
Analytical Hierarchy Process (AHP) is a model to quantify situations involving multiple 
criteria for organizing and analyzing complex processes. Rather than prescribing a “correct” 
decision, the AHP helps finding the decision that suits the goal and their understanding of the 
problem. It provides a comprehensive and rational framework for structuring a decision problem, 
for representing and quantifying its elements, for relating those elements to overall goals, and 
for evaluating alternative solutions. 
There are 4 steps to be followed while implementing the AHP process: 
1- Decision Hierarchy 
 Break down the problem into decision elements – criteria and alternatives 
 The overall goal is placed at the top; the remaining attributes bellow 
                                        
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2- Pairwise Comparisons of Decision elements 
 
 Compare all pairs of elements in one level with respect to the previous level 
 The comparisons are organized in matrixes     (  = number of alternatives in 
each level) 
 Main diagonal must consist 1. 
 1 2 … n 
1 1 A12 … A1n 
2 a21 1 … A2n 
… … … 1 … 
n an1 an2 … 1 
 
 Comparison based in a 1 to 9 scale – Saaty`s scale: 
 
Intensity of relative importance Definition 
1 Equally important 
2 Intermediate importance value 
3 A is weekly more important than B 
4 Intermediate importance value 
5 A is moderately more important than B 
6 Intermediate importance value 
7 A is strongly more important than B 
8 Intermediate importance value 
9 A is absolutely more important than B 
 
 
3- Assessment of the Consistency of Decisions taken 
Decisions taken by the decision elements Valid and Consistent 
 Consistency Ratio (CR) correspondent to each matrix: 
 
   
  
  
 
        
      
  
              with        
Level 3 
Level 2 
Level 1 Problem 
Criterion 1 Criterion 2 
Alternative 
1 
Alternative 
2 
Alternative 
y 
Criterion x 
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In which: 
    - largest or principal eigenvalue 
  - Constancy index 
  - Random consistency index 
  –order matrix 
 
 Typical values for the RI 
N 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
RI 0 0 0.58 0.90 1.12 1.24 1.32 1.41 1.45 1.49 1.51 1.48 1.56 1.57 1.59 
 
 
4- Determination of relative weights 
 
                 
                     
                         
 
 
 A B C D PV 
A 1 5 7 9 0.589 
B 1/5 1 3 5 0.247 
C 1/7 1/3 1 3 0.120 
D 1/9 1/5 1/3 1 0.044 
     1 
 
 
 
4.5.7 Hazard Analysis and Critical Control Points (HACCP) 
 
HACCP is a systematic, proactive and preventive tool for assuring quality, reliability and 
safety. It involves hazard analysis, determining critical control point, establishing critical limit, 
establishing a system to monitor critical control point and establishing a record keeping system. 
This might be used to identify and manage risk associated with physical, chemical and 
biological hazards. 
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Figure 44: HACCP Seven Principles 
•Potential hazards to the products quality are recognized; in addition measures 
to regulate and control the hazards are identified. Analyze Hazards 
•Critical control points throughout the production process of the product are 
established. Identification of CCPs 
•  A preventive measure is established at all CCPs: for e.g. minimum sparging time 
or bulk temperature at bulk holding time. 
CCP Preventive 
Measures 
•A system is established to monitor prevention measures at a CCP: for e.g. a 
digital termometer in the  tankwill monitor and log the temperature. 
Monitoring of CCP 
Preventive Measures 
•Establish a precaution when the CCP hasn`t been met: for e.g. if the 
temperature is too high the thermometer will alarm and cooling is re-started.  CCP Not Met 
•Maintain a log system of all the CCPs; also, this would include records of CCP 
control methods and action taken to correct potential problems. HACCP & CCP Log 
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Chapter 5 RESULTS – Assess Products` Risk 
Framework 
 
The goal of Hikma Risk Analysis approach is aligned with ICH and FDA guidelines 
described in Chapter 2 - LITERATURE OVERVIEW; especially around tracking Critical Quality 
Attributes (CQAs) and Critical Process Parameters (CPPs) in a pragmatic manner. 
 
5.1 Injectables Manufacturing Processes 
 
In order to evaluate the risks associated to the sterile production of injectable products, it is 
crucial to identify the operational pharmaceutical units of the process. There are raw-materials 
and inputs, process controls, and product attributes associated with every unit operation in a 
manufacturing process. In Figure 45 it is exemplified a process flow-chart for an injectable 
product. 
 
Figure 45: Flow-chart e.g. of an Injectable Manufacturing Process 
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A typical process consists of a series of unit operations. In order to develop a robust 
process, units of operations have to be studied and the process parameters and attributes have 
to be defined. In general, flow charts are used to define the process. This flow-chart should 
have sufficient detail to readily understand the primary function of each step. Figure 45 
illustrates a general process flow-chart for HIKMA injectable product. It is important to underline 
that all components and processes involved in the preparation of injectable products must be 
selected and designed to eliminate, as much as possible, contamination of all types. Aseptic 
processing is the most demanding of pharmaceutical processes. It requires precise attention to 
operator training and behaviour, process validation, production process documentation, plant 
and equipment maintenance and quality risk managing the changes. 
 
5.2 Injectable Manufacturing Variables: Sources 
 
To meet the requirement of exhaustiveness of hazards and risks evaluation and reviewing, 
the project methodology initially proceeded to the inventory of all activities implemented in the 
process covered by Hikma quality system.  
 
Figure 46: Cause and Effect Diagram with CPP from Manufacturing Process of Injectable Products 
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The process operations are considered the major contributors that cause the starting 
materials to be converted to final product. Although this seems complex at first, manufacturing 
processes of different injectable forms share some similar process steps. The scope to assess 
products risks` framework starts by understanding and evaluating process inputs in order to set 
the control strategy. It is this combination of process inputs and CQA, complemented by a 
control strategy that proves a manufacturing quality new product or at commercial scale. In 
Figure 46 are identified the general causes of Hikma injectable products and processes that 
may have an impact on product quality. 
 
5.3 Critical Process Parameters (CPPs) 
 
A list of general Process Parameters common to Hikma Injectables manufacturing was 
listed (Figure 7), which are potential CPPs dependent on the product specificities. The in-
process and finish product controls monitor the process but the aim of this project is to reduce 
the risk to an acceptable level by introducing additional controls in the manufacturing process, 
facility or equipment. According to a risk evaluation this potential CPPs may turn out to be 
considered CPPs or CCPs (Critical Control Parameters). These activities were divided into 
elementary steps, which are then individually introduced in the decisional risk assessment tool. 
 
Table 7: Specifications of Process Parameters and general IPC and Finish Product Controls 
 Manufacturing 
Process Activities 
Common Process Parameters for  Injectable 
Products (potential CPPs) 
Controls of Intermediate 
Products and Finished 
Products 
Materials / 
Equipment 
preparation 
 Temperature / time of material sterilization 
 Define Sterilization loads 
 Clean and dirty hold time 
 Equipment drying time 
 Cleaning processes 
 Weighing of Raw-materials 
 Materials compatibility 
Bioburden 
Endotoxins 
Cross-contamination 
Compounding  Stainless steel tank 
 Mixing speed / time 
 Flow of Nitrogen 
 Total holding time 
 Light sensitivity 
 Heat / cold sensitivities 
 Samples storage conditions 
Temperature 
Dissolved Oxygen 
Assay 
Density 
pH 
Assay 
Related substances 
Filtration  Filtered compressed Air / Nitrogen  
 Filters (autoclaved) drying time 
 Filters contact time 
Assay 
Density 
pH 
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 Manufacturing 
Process Activities 
Common Process Parameters for  Injectable 
Products (potential CPPs) 
Controls of Intermediate 
Products and Finished 
Products 
 Filter Compatibility with product 
 Filtration pressure 
 Filtration flow-rate 
 Filtration temperature (according to 
validation) 
 Type of sterilizer filter 
 Integrity test to the filter 
 Aseptic technique 
Bioburden 
Filter validation studies 
Filling  Temperature 
 Fill volume 
 Speed of filling 
 Nitrogen overlaying 
 Aseptic technique 
Volume / Weight variation 
Color/ clarity (if applicable) 
Assay 
Related substances / Purity 
pH 
Oxygen headspace 
Endotoxins 
Sterility 
Lyophilisation 
(if applicable) 
 Product temperature 
 Freeze dryer shelves temperature 
 Chamber pressure 
Appearance 
Reconstitution time 
Leak test 
Uniformity of content 
Uniformity of mass 
Assay 
Water content 
pH 
Related substances 
Particles after reconstitution 
Endotoxins 
Sterility 
Final Sterilization 
(if applicable) 
 Temperature / time of product sterilization Sterility 
Assay 
Related substances 
Inspection  Finish Product quality attributes – optical 
inspection machine / visual inspections 
Particles 
Defects 
 
In agreement to Process Validation guidance from FDA (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011) quality cannot be adequately 
assured merely by in-process and finished-product inspection or testing as described summarily 
in the above table (Table 7). Quality cannot be tested into products; it should be built-in or 
design-in. 
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A risk analysis prepared in this work will comprehensively identify and document risks, and 
furthermore, develop solutions that can reduce or eliminate the identified risks and minimise the 
scope of the subsequent qualification testing. Arriving at an accurate risk profile is difficult, but 
needed, to identify risk and subsequently manage or mitigate the threats and vulnerabilities that 
create potential variability. The difficulties of creating a risk profile for each injectable product 
will be minimized or even outdated with Hikma Risk Assessment Tool created in this project. 
 
5.4 Hikma Risk Approach – Assess Products` Risk Framework 
over entire Product Lifecycle 
 
Process validation demonstrates consistency of the process at NOR. Lifecycle approach 
makes process validation an ongoing activity that enables ongoing assurance gained since the 
first produced batches (Product Performance Qualification) during routine production that the 
process remains on state of control (Figure 47).  
 
 
 
Figure 47: Strategy approach for products design space verification over lifecycle of different forms of Hikma Injectable 
Products - Hikma Process Validation Program of Injectable Products Lifecycle.; no temporal relationship is intended. 
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Each process designed intents to define the commercial process on knowledge gained 
through development and scale-up activities. The outcome is the design of a reproducible 
process suitable for routine manufacture that will consistently deliver product that meets its 
CQA. Once a manufacturing process has been tested to the extent that the test results are 
predictable, further testing can be replaced by establishing that the system was operating within 
a defined design space. Based on this scheme on Figure 47 was designed to clarify the 
suggested procedure to build quality into processes - Hikma Process Validation Program of 
Injectable Products Lifecycle.   
In both (FDA and EMA) agencies` experience, the design space verification at commercial 
scale is not necessarily complete at the time of submission of the product but should happen 
over its lifecycle. However, movements from one NOR to another NOR within the approved 
design space (in an unverified area) may pose higher or/ and unknown risks due to potential 
scale-up effects, new equipments, model assumptions, etc. Also, three batches run early in 
lifetime of a product cannot be expected to represent its process a decade later or beyond. 
Therefore FDA and EMA came with the announcement, last October (2013) for a new guideline 
in which is described that is essential to understand and evaluate those risks, utilizing an 
appropriate control strategy, including but not restricted to the controls submitted in the dossier.  
Moreover, Hikma must be able to adequately explain and defend the choices that it makes 
to the authorities. In the end it is the data and the operational metrics that are taking in 
consideration and not the number of batches. This is achieve by this systematic approach to 
development that begins with predefined QTPP and emphasize the product and process 
understanding and its controls based on quality risk management and science. In addition, look 
to process parameters and unit operations that impact CQA and further control strategies will 
support the choice of operating range that is critical and must be verified over product lifecycle 
for commercial scale. In practice, the suggested approach for QRM in Hikma to evaluate and 
improve the quality assurance of production can progress following some initial steps: 
 
1) Evaluation of System State of Control - Risk Assessment 
2) Description of Process Controls and Process Characterization 
a) The sampling plan is adequate  
b) The system is stable  
c) The system is capable  
3) Design space 
4) Risk Reviewed by Quality and Risk Communication  
5) Cleared for distribution 
6) Continuous Product Verification 
 
Below are described in detail the activities as a guideline for an Process Performance 
qualification of Tech Transfer batches, New Products, Processes changes and Continuous 
process verification. 
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1) Evaluation of System State of Control - Risk Assessment 
 
In order to make possible a risk approach for Process validation a general methodology 
was defined for Hikma Risk Assessments. This risk approach has the objective to improve the 
way the process is defined and also identifies crucial areas and/ or steps in the process, areas 
of risk and or hazard, and critical control points. Mainly this step should be followed for a new 
product development nevertheless an existent process (or part of the process) re-evaluation 
can also start at this stage (e.g. scale-up). Undoubtedly, products risk assessment is created for 
products`life. 
 
Figure 48: Hikma 9 Steps Approach for Products Risk Assessment 
 
 
Type of product 
 Define Production line 
 Evaluate Formulation 
 Detail Manufacturing process 
 Describe product materials compatibilities 
 Evaluate sensitivities (heat, air, light) 
 Define container closure 
 
Risk Assessment 
1 
• Type of Product 
2 
• Collect and Organize Product and Process information 
3 
• Formulate the risk question 
4 
• Identify Risk Factors, Hazards 
5 
• Define Risk Components scales 
6 
 
• Define Criticality (Risk evaluation) 
 
8 
• Define Risk Components scales (RPN value calculation) - Apply Risk 
Tools - Chapter 4 
9 
• Determine Action Threshold 
10 
 
• Document and Approve 
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Collect and Organize Product and Process information 
 Gathering relevant information, reviewing appropriate references and identifying 
assumptions 
 Statistical tools (Chapter 4) can be used to organize information 
 Define the boundaries of the QRM exercise – specific process step validation,  
all manufacturing process validation, investigation, scale-up process, new API 
source validation, ...) 
 
Formulate the Risk Question 
Starting point of the QRM exercise, high level statement outlines the issue and purpose for 
conducting the QRM exercise including risk factors, the scope of the issue and any related limits 
or constrains.  
 
Identify Risk Factors, Hazards 
This project phase combines technology with the experience of people to identify potential 
failure modes of the product or manufacturing process dependent on what is being validated. 
 
Define Risks Components and scales 
In terms of a QRM exercise to create a valuable schedule the following risk components 
scales (Table 8) were defined: 
 Severity of harm – a measure of the possible consequences or degree of 
harm; 
 Probability of harm will occur – frequency or likelihood of occurrence of the 
hazard; 
 Detection of risk – the ability to discover or determine the existence, or 
presence of the hazard 
 
Figure 49: Detectability of risk over product lifecycle determined based on people experience. 
A Product life cycle = RISK 
FUTURE 
(Can you 
find it?) 
TODAY  
(Data refer 
to) 
PAST  (Data 
refer to) 
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Table 8: Key to construct the assessment tool for each product 
Severity (S) Scale definition 
1 
Effect does not have any impact on internal procedures or regulatory requirements. Effect 
has no impact on product quality. 
2 
Effect has minor impact on internal procedures and may result in minor regulatory 
observations. Effect has minor impact on product quality. 
3 
Effect has moderate impact on internal procedures and may result in regulatory 
observations. Effect has minor impact on product quality. 
4 
Effect has major impact on internal procedures and may result in regulatory observations. 
Effect has impact on product quality. 
5 Effect may lead to critical regulatory observation and may result in product failure. 
Occurrence (O) Scale definition 
1 Remote probability of occurrence. Occurence is rarely. 
2 Low probability of occurance. Occurence is not frequent. 
3 Moderate probability of occurence. Occurence is periodic. 
4 High probability of occurence. Occurrence is frequent. 
5 Very high probability of occurence. Certain to occur. 
Detection (D) Scale definition 
1 Very high likelihood of detection. Current controls will almost certainly detect cause of failure. 
2 High likelihood of detection. Current controls may not detect cause of failure. 
3 Moderate likelihood of detection. Current controls may not detect cause of failure. 
4 Low likelihood of detection. Current controls will most likely not detect cause of failure. 
5 Remote likelihood of detection. Current controls will very likely not detect the cause of failure. 
 
Define Criticality (Risk evaluation) 
It compares the identified and analysed risk against given risk criteria. Risk evaluations 
consider the strength of evidence for Criticality and Detection. 
 
Table 9: Calculation for Criticality 
 
 
 
 
 
 
Determine Action Threshold 
A level or value above which an action will take place and below it will not. 
 
 
S x O 1 2 3 4 5 
1 1 2 3 4 5 
2 2 4 6 8 10 
3 3 6 9 12 15 
4 4 8 12 16 20 
5 5 10 15 20 25 
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Define Risks Components scales 
In order to facilitate the process validation study initiation a general tool for Hikma 
Risk Assessment was created (Table 11), where the main potential variations for an 
injectable product manufacturing are summarized. This tool can be applied to different 
products as the scores are attributed for severity, probability and detection (Table 8) 
dependent on each product and the risks impact on CQA. In addition the actions 
required based oon the obtained threshold are detailed for each risk. 
This tool can be used to evaluate / study a specific process phase (as it is divided 
into sections) or the all manufacturing process of an injectable product. Since 
processes are not static over the product life also the critical aspects can change and/ 
or new risks might come into sight, and consequently this tool should be continuously 
optimized. Furthermore, the reports numbers for the studies relative to each product / 
vial / stopper / line should be added in where it is appropriate in order to facilitate the 
assess to relevant risk information on the table. This tool can be customized over the 
years in order to be more specific for each Hikma production line covering more items 
and also to be modified to new lines. Recently, new products with much specificity 
(extreme temperatures, low headspace oxygen, etc.) are being developed due to 
technological improvements ending in more complex manufacturing processes.  
 
Table 10: Calculation of Risk Priority Number (RPN) 
 
 
 
 
 
 
 
 
 
 
 
D 
    
S x O 1 2 3 4 5 
25 25 50 75 100 125 
20 20 40 60 80 100 
16 16 32 48 64 80 
15 15 30 45 60 75 
12 12 24 36 48 60 
9 9 18 27 36 45 
8 8 16 24 32 40 
6 6 12 18 24 30 
5 5 10 15 20 25 
4 4 8 12 16 20 
3 3 6 9 12 15 
2 2 4 6 8 10 
1 1 2 3 4 5 
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Table 11: Risk Assessment for Hikma Injectable Products – Critical Process Parameters 
Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
warehouse/ 
preparation for 
compounding 
W1 Weighing of API Incorrect weight. 
Low or high 
assay results 
(OOS bulk IPC); 
batch failure. 
  
Wrong calibration of 
the scales. Human 
error during weighing.  
  
IPC assay (fill volume 
adjustment in order to 
compensate the difference on 
potency). Scales are calibrated 
daily. All weights are triple 
verified by both compounding 
operators and QA. 
  0 0 
No RISK no 
further test 
is required 
Comparation of Hikma 
CoA results with 
Supplier CoA results in 
order to confirm the 
results are aligned.  
W2 
Weighing of 
Excipients 
Incorrect weight. 
Bulk solution IPC 
OOS. Finished 
Product OOS. 
Reduced 
stability. 
  
Wrong calibration of 
the scales. Human 
error during weighing.  
  
Scales are calibrated daily. All 
weights are double verified by 
both compounding operators 
and QA. 
  0 0 
No RISK no 
further test 
is required 
Controlled conditions to 
weight hygroscopy raw-
materials. Low 
ventilation to weight 
light and fluffy powders. 
W3 
Raw-Materials  
storage 
(sensitivities) 
Raw-materials 
not overlayed 
with nitrogen; 
Not protected 
from light; not 
stored under 
appropriate 
conditions 
Raw-materials 
degradation 
(high content of 
impurities) and 
decrease of 
potency 
  
Human error (storage 
conditions not 
followed); If raw 
materials is not kept 
in the original 
container until 
production day. 
  
All Raw-materials are sampled 
under laminar flow and the top 
of the containers overlayed 
with Nitrogen; here are specific 
instructions in SOPs and batch 
records 
  0 0 
No RISK no 
further test 
is required 
Raw-materials included 
in SOP compiling the 
conditions for the 
weighing 
W4 
API calculation to 
adjust potency 
Added amount 
of API is higher 
or lower than 
required 
Low or high 
assay results 
(OOS bulk IPC); 
batch failure 
  
API assay, Water 
content or Solvents 
wrongly reported in 
the CoA used for 
calculations; Human 
error in calculations 
  
Calculation of API is double 
verified bedsore weighing and 
recorded in the MBR.  All 
weights are double verified by 
both compounding operators 
and QA. 
  0 0 
No RISK no 
further test 
is required 
Formulas for API 
calculation adjustment 
revised by Quality Unit 
Director or QC Manager 
at the moment of Batch 
records approval 
Compounding C1 
Initial WFI / oil / 
liquid excipient 
weighing in the 
compounding 
tank 
Incorrect weight. 
Low or high 
assay results 
(OOS bulk IPC); 
batch failure. 
  
Wrong calibration of 
the scales. Human 
error during weighing.  
  
Scales are calibrated daily. All 
weights are double verified by 
both compounding operators 
and QA. 
  0 0 
No RISK no 
further test 
is required 
N/A 
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Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
C2 
DO in bulk 
solution (or 
initial solution 
purged with 
filtered Nitrogen) 
Oxygen content 
higher than x 
mg/ L 
API degradation. 
Preservatives (if 
present) that 
reduce the 
reactive oxygen 
in solution are 
consumed 
immediately. 
Reduced product 
stability. 
  
Oxygen sensor 
malfunction. Human 
errors (high mixing 
speed allow oxygen in 
the solution; tank not 
closed after purging) 
  
Control of DO in solution using 
an oxygen sensor daily 
calibrated. 
  0 0 
No RISK no 
further test 
is required 
Oxygen sensitivity and 
stability studies for 
different headspace 
oxygen percentages. 
C3 
Dissolution of 
API 
Insufficient 
mixing time and/ 
or speed; or over 
mixing 
Incomplete 
dissolution of 
API; Bulk solution 
does not need 
IPC specifications 
  
Human error; 
incorrect visual 
evaluation of 
dissolution 
  
Mixing speed in vortex is 
evaluated during all PPQ 
batches in order to validate a 
range. Samples are taken from 
the bottom for visual check of 
API dissolution. 
  0 0 
No RISK no 
further test 
is required 
Closely monitored 
during validation studies 
(time and mixed speed) 
C4 
Foam formation 
during mixing for 
raw-materials 
dissolution / 
sparging with 
filtered nitrogen 
Flow rate of 
nitrogen 
sparging is high 
or mixing speed 
is high. 
Product (foam) 
comes out from 
the tank; high 
DO with no 
possibility to 
continue 
sparging; visual 
confirmation of 
raw-materials 
dissolution is 
impossible. Bulk 
IPC OOS, 
  
Human error; 
insufficient 
monitoring of batch 
preparation 
  
Products forming foam are 
compounded in bigger tanks 
size than the set batch size. 
Nitrogen overlay helps to 
control the foam. 
  0 0 
No RISK no 
further test 
is required 
Prior to PPQ confirm the 
possibility of bulk 
solution forms foam; 
and design the process 
with an appropriate 
tank size for 
compounding 
accordingly 
C5 
Product light 
protection 
tank entrance 
not closed or 
covered with 
aluminium foil 
between raw-
materials 
addition 
API degradation.  
Reduced product 
stability. 
  Human error.   
Operators are trained in 
product specificities and 
sensibilities. No other controls 
are implemented. 
  0 0 
No RISK no 
further test 
is required 
Photostability studies. 
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Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
C6 
Dissolution of 
Excipients 
Insufficient 
mixing time and/ 
or speed; or over 
mixing 
Incomplete 
dissolution of 
API; Bulk solution 
does not meed 
IPC specifications 
  
Human error; 
incorrect visual 
evaluation of 
dissolution. 
  
Mixing speed in vortex is 
evaluated during all PPQ 
batches in order to validate a 
range. Samples are taken from 
the bottom. 
  0 0 
No RISK no 
further test 
is required 
Reference time for 
mixing of excipients in 
development report.  
Industrial mixing times 
and speeds for specific 
batch in specific tank 
detailed in Validation 
Report. 
C7 
Preparation 
Holding time 
Excessive hold 
time from the 
API addition to 
the end of 
compounding / 
beginning of 
lyophilisation 
cycle OR if 
volatile 
excipients in 
formulation (e.g. 
ethanol) long 
holding times for 
preparation will 
reduce their 
content in 
solution  
Increase of 
impurities 
  
Product is not stable 
for long time in liquid 
state. Human error, 
mechanical problem 
in the line can lead  to 
exceeding the bulk 
holding time. 
  
All critical times have to be 
studied and documented in the 
batch record. Solution is stored 
in sealed tank. 
  0 0 
No RISK no 
further test 
is required 
Maximum holding time 
between API addition 
and beginning of 
freezing  phase to be 
evaluated for lyophilized 
products 
Or  for liquid products - 
Maximum holding time 
between API addition 
and end of filling. 
C8 
 Heating or 
cooling the 
solution 
Temperature 
above or below 
the set limits 
Increase of 
impurities. 
Dissolution 
difficulties 
 
Human error, 
mechanical problem 
(in chiller or heater) 
 
Temperature limits for 
applicable steps are written in 
the batch records and are 
double check by 2 compouding 
operators. 
 
0 0 
No RISK no 
further test 
is required 
Closely monitored 
during validation studies 
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Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
C9 pH adjustments 
pH not in the 
required range 
Reduced buffer 
capacity; 
Reduced stability 
  
Human error, pH 
meter pH meter not 
correctly calibrated 
  
pH meter is calibrated daily. pH 
specified in batch record and 
pH readings are double verified. 
After all adjustments QC 
confirm 
  0 0 
No RISK no 
further test 
is required 
Expected amount of pH 
adjustment solutions 
mentioned in 
Development report 
C10 
Liquids 
excipients with 
high viscosity 
Not totally 
transferred to 
preparation tank 
Low or high 
assay 
(compromise the 
batch) 
  Human error   
If these liquids are not weight 
directly in the preparation tank, 
there are other actions as 
mechanical removal with WFI or 
container wash with bulk 
solution from the compounding 
tank (if not removed with 
another organic solution) 
  0 0 
No RISK no 
further test 
is required 
Weighing procedures 
adjusted to different 
materials viscosities in 
order to reduce losses 
C11 Final Q.S. 
Human error; 
balance 
malfunction 
Low or high 
assay 
(compromise the 
batch) 
  
Human error, scale 
malfunction 
  
Balance is calibrated and 
verified prior to each 
compounding as per SOP. The 
Q.S. is double verified. 
  0 0 
No RISK no 
further test 
is required 
Quantify the water 
amount to be added to 
the final Q.S. 
C12 Tank Transfer 
Product losses; 
Contamination; 
materials 
incompabilities 
Bioburden OOS;  
High RS content 
  Human error.   
All tanks are cleaned and 
sterilized using validated 
procedures. The compatible 
materials with product are 
described in the batch record. 
The tank holding time after 
CIP/SIP is qualified. The product 
holding time in the transference 
tank is validated for a certain 
time (can be up to 72 h). 
  0 0 
No RISK no 
further test 
is required 
Validation study for 
product transference. 
Bulk holding time in 
transference tank. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
C13 
Bulk Solution 
Sampling 
Incompatibility 
with containers; 
Contamination; 
use of non-
dedicated or 
disposable 
materials; 
incorrect 
sampling 
procedures; 
product 
oxidation 
High results for 
related 
substances and 
low assay results; 
high bioburden; 
products cross 
contamination; 
assay OOS. 
Results not 
representative of 
bulk solution 
(false results). 
Batch failure. 
  
Incorrect sampling 
procedures. Wrong 
sampling containers 
used.  High headspace 
oxygen inside the 
sampling container 
that can react with 
the product. 
  
Surfaces compatibility studies 
are made for Hikma products 
and requested for clients' 
products; Operators are trained 
in compounding GMPs every 
year; for oxygen sensitive 
products the sampling 
container has to be totally filled 
l no avoid headspace. 
  0 0 
No RISK no 
further test 
is required 
Batch sampled in 
different containers for 
compatibility surfaces 
studies. 
Sterilization of 
equipment and 
materials 
S1 
Sterilization and 
Depyrogenation 
of glass 
containers 
Cycle parameters 
not met.  
Non sterile and 
pirogenic 
containers, 
broken 
containers. 
  
Human error , 
mechanical problem, 
probes not calibrated. 
  
Probes calibrated on annual 
basis; cycle specified in batch 
record and SOP, all 
documentation reviewed after 
sterilization. Sterilization cycle 
parameters validated for each 
type of vials. 
  0 0 
No RISK no 
further test 
is required 
Validation report for 
vials (size, moulded or 
tubular) sterilization/ 
depyrogenation in the 
tunnel 
S2 
Sterilization of 
stoppers and 
machine parts 
Materials are not 
sterilized  
utilizing the 
validated 
parameters 
(cycle and load 
configuration) 
Not sterile 
stoppers / parts 
  
Human error, 
mechanical problem 
  
Probes calibrated on annual 
basis, cycle specified in batch 
record and SOP, all 
documentation/print 
outs/alarms reviewed after 
sterilization. Loads validated. 
  0 0 
No RISK no 
further test 
is required 
Report for Loads 
validation exists 
Filtration  FT1 
Filtration (and 
pre-filtration) 
Filter non-
integral  
Filled product 
non sterile; High 
Bioburden 
results after pre-
filter 
  
Human error; faulty 
filter 
  
Each filter has a "Certificate of 
test" from supplier. New filter 
used each production and pre- 
and post- integrity test are 
conducted before and after 
production, respectively.  
  0 0 
No RISK no 
further test 
is required 
Filter supplier Certificate 
of test (Bubble point 
test or diffusion flow 
test) 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
FT2 
Filtration (and 
pre-filtration) 
 Filter non 
compatible with 
product  
Low assay, high 
impurities 
  
Materials not 
compatible with 
product; product 
conditions 
(temperature and pH) 
different from what is 
validated 
  
The same filter membrane was 
used during R&D batches and 
stability is conforming. Filter 
validation studies performed 
with product, by filter supplier. 
  0 0 
No RISK no 
further test 
is required 
Supplier filter validation 
studies (Bacterial 
Challenge, 
Compatibility, 
Extractables) 
FT3 Final filtration Filter clogging 
Bulk solution not 
total filtered/ 
Low yield of 
filled units 
  
Not appropriated 
filter size 
  Filterability studies performed.   0 0 
No RISK no 
further test 
is required 
Filterability studies 
Aseptic Filling 
FL1 
Machine set-up  
 
 
Effect of filling 
equipment 
Incompatibility 
of filling contact 
parts materials 
with the product 
leading to 
leachables and 
potential 
adverse 
reactions. 
Incorrect tubing, 
adverse 
reactions. Not 
filling under 
nitrogen/inert 
gas if the 
product is 
oxygen sensitive 
Low assay and 
high impurities 
  
  
Materials used during 
filling are not 
compatible with 
product. 
 
Human error / 
materials 
incompabilities 
  
  
Tubing and equipment to be 
used is specified in the batch 
record. Surfaces 
incompatibilities studied during 
R&D batches. 
 
Equipment and materials are 
specified in the batch record. 
An initial flushing to the filling 
line is performed (if validated a 
specific volume to discard is 
described in the batch record). 
Surfaces compatibility studies 
are done for each product. 
The need of filling under 
nitrogen is also specified on the 
batch record. 
  
  
0 0 
No RISK no 
further test 
is required 
Surfaces compatibility 
study. 
 
Oxygen sensitivity 
studies. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
FL2 
Volume 
adjustments 
Incorrect volume 
adjustment 
-Product  
collapse during 
Lyophilisation 
process; mass 
and volume of 
product 
exceeding 
amount of 
solvent that can 
be removed 
during 
processing 
(overfill for 
lyophilized 
products: 
-Product , high 
assay result 
- Low assay 
result (under fill) 
  
Improper control of 
filling vials / machine 
malfunction / wrong 
IPC balance 
calibration 
  
Start of filling is confirmed by 3-
10 vials within the limits. 
Weight checks during filling and 
visual inspections at the end of 
the process 
  0 0 
No RISK no 
further test 
is required 
Filling machine is 
capable of fill the 
product in the specific 
vial size within the 
specified volume limits 
 
PPQ for fill volume. 
FL3 
Effect of filling 
process 
procedures 
Routine filling 
interventions / 
Interventions 
due to any 
mechanical 
problem 
non sterile 
product (safety 
and quality 
problem) 
  
Operators not 
qualified in each 
intervention/ human 
error 
  
Filling process is covered by 
media fill. 
  0 0 
No RISK no 
further test 
is required 
Media fill report 
covering the vial size 
and filling procedures/ 
interventions 
FL4 Filling line speed 
fill volume 
variations 
Extractable 
volume (if liquid) 
or Uniformity of 
content (if lyo) 
OOS; batch 
failure. 
  
Fill line speed not 
studies or  wrong 
parameters set in the 
batch record. 
  
Acceptable proven filling speed 
range is documented in the 
batch record.  
  0 0 
No RISK no 
further test 
is required 
Acceptable Proven 
Filling speed range study 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
FL5 
Effect of Filling 
stoppages 
Increase time for 
product contact 
with surfaces 
and temperature 
variations of 
product inside 
the filling 
machine 
Low assay, high 
impurities 
  
Maintenance 
interventions due to 
technical problems; 
  
Actions to be taken after a 
stoppage  stated on the MBR 
  0 0 
No RISK no 
further test 
is required 
Impact of stoppages up 
to 2 hours study 
Lyophilisation 
LY1 
Evacuation 
Vials completely 
closed ( not 
partially 
stoppered) 
Potential for 
collapse of 
product 
  
Stoppering failure 
during filling / human 
error 
  
Visual control by filling 
operators during the entire 
filling 
  0 0 
No RISK no 
further test 
is required 
 Special training to filling 
operators in the 
difference of filling a 
liquid and a lyo product 
LY2 
Shelf 
temperature too 
high 
Potential for 
partial collapse 
on top of 
product 
  
Malfunction of shelf 
temperature control 
system 
  
Calibration of temperature 
sensors and control loop PM of 
temperature control 
components  
    0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY3 
Shelf 
temperature set 
point too high 
Potential for 
partial collapse 
on top of 
product 
  
Selection of incorrect 
lyophilisation 
program 
  
Supervisor training and batch 
record / SOP control (lyophilizer 
alarms) 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
LY4 
Chamber 
pressure too 
high 
Potential for  
collapse on top 
of product 
  
Excessive frost build-
up on shelves 
  
Loading area humidity control 
and batch record limits (if any) 
on duration of loading 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY5 
Pressure set-
point incorrect 
Potential for  
collapse on top 
of product 
  
Water from 
sterilization cycle. 
Selection of incorrect 
lyophilisation 
program 
  
PM of unit and visual detection 
by operator. Operator training 
and batch record control. 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY6 
Product Primary 
drying 
Shelf ramp to 
primary drying 
too fast 
Melt back or 
collapse 
  
Malfunction of shelf 
temperature control 
system.  
  
Calibration of temperature 
sensors and control loop PM of 
temperature control 
components 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY7 
Shelf 
temperature too 
high 
Rapid drying, 
potential for 
product collapse 
  
Selection of incorrect 
lyophilisation 
program; Malfunction 
of shelf temperature 
control system 
  
Operator training and batch 
record / SOP control; 
Calibration of temperature 
sensors and control loop PM of 
temperature control 
components. 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
LY8 
Shelf 
temperature too 
low 
Slow drying, 
potential for 
incomplete 
primary drying 
and collapse in 
transition to 
secondary drying 
  
Malfunction of shelf 
temperature control 
system.  
  
Calibration of temperature 
sensors and control loop PM of 
temperature control 
components 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY9 
Shelf 
temperature set 
point too low 
Slow drying, 
potential for 
incomplete 
primary drying 
and collapse in 
transition to 
secondary drying 
  
Selection of incorrect 
lyophilisation 
program 
  
Operator training and batch 
record / SOP control. 
  0 0 
No RISK no 
further test 
is required 
R&D lyophilisation  cycle 
development; Executed 
lyo cycles prints-outs 
evaluated versus 
approved lyophilization 
cycle. Lyophilization 
cycle alarms evaluated. 
LY10 
Step duration 
too short 
Product collapse 
or excessive 
moisture 
  
Selection of incorrect 
lyophilisation 
program; Malfunction 
of timer system; Trays 
used to dry product 
warped or changed; 
Heat transfer 
characteristics of 
scaled -up lyophilizer 
different from those 
of previous unit; Less 
extraneous heat 
available compared to 
previous unit; Larger 
load, less edge 
effects. 
  
Operator training and batch 
record / SOP control; Periodic 
requalification of 
microprocessor controller; 
Batch record control, PM on 
tray, inspection of trays during 
process; Qualification of 
lyophilizers. 
  0 0 
No RISK no 
further test 
is required 
Consider sublimation 
studies to compare 
sublimation rates in 
scale-up and previous 
lyophilizer, cycle 
modification. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
LY11 
Chamber 
pressure too 
high 
Potential for 
product collapse 
(during primary 
drying) high 
moisture 
  
Selection of incorrect 
lyophilisation 
program; Malfunction 
of chamber pressure 
control system; 
Different pressure-
sensor operating 
characteristics than 
those used in 
previous lyophilizer; 
Condenser capacity 
insufficient 
  
Operator training and batch 
record / SOP control; 
Calibration of pressure sensors 
and control loop PM of pressure 
control components; 
Equipment design 
specifications, qualification 
studies. 
  0 0 
No RISK no 
further test 
is required 
Compare operating 
characteristics of 
lyophilizers as part of 
technology transfer 
LY12 
Chamber 
pressure control 
too low 
Potential for 
incomplete 
primary drying 
(collapse in 
transition to 
secondary 
drying) 
  
Selection of incorrect 
lyophilisation 
program; Malfunction 
of chamber pressure 
control system; 
Different pressure-
sensor operating 
characteristics than 
those used in 
previous lyophilizer.  
  
Operator training and batch 
record / SOP control; 
Calibration of pressure sensors 
and control loop PM of pressure 
control components. 
  0 0 
No RISK no 
further test 
is required 
Compare operating 
characteristics of 
lyophilizers as part of 
technology transfer 
LY13 
Product 
secondary drying 
Ramp to 
secondary drying 
too severe 
Potential product 
collapse, 
excessive heating 
for partially wet 
cake. 
  
Selection of incorrect 
lyophilisation 
program; Malfunction 
of shelf temperature 
control system; 
Condenser capacity 
insufficient. 
  
Operator training and batch 
record / SOP control; 
Calibration of pressure sensors 
and control loop PM of pressure 
control components; 
Equipment design 
specifications, IQ/OQ studies. 
  0 0 
No RISK no 
further test 
is required 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
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FMECA - Failure Mode Effects and Criticality 
Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on Entire 
System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probability 
of 
Occurrence 
Risk Reduction and Risk 
Evaluation/Process Controls 
(D) 
Probability 
of 
Detection 
Criticality 
RPN 
value 
CONCLUSI
ON 
Validation/ 
Verification STUDY to 
be done 
Manufacturing 
Process Phase 
Identific
ation of 
Process 
Step 
Phase to which 
belongs the 
process step 
RISK 
Probable 
consequences / 
OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 
5 high] 
Incorrect INPUTS 
From 1 to 
5 [1=rare; 
5 
frequent] 
Variability Control 
From 1 to 
5 [1=high; 
5 low] 
S x O 
SxOx
D 
Step Risk 
Additional Controls / 
Tests to be 
implemented during 
Process Validation 
LY14 
Lyophilizer PLC 
error 
High water 
content, high 
impurities and 
non-conforming 
cake 
Batch failure   
Lyophilizers have 
alarms. Verification of 
lyo cycle is done for 
pressure, 
temperature and time 
by supervisors along 
the cycle duration. 
Key people are 
informed if any  
  
Lyophilizers have alarms. 
Verification of lyo cycle is done 
for pressure, temperature and 
time by supervisors along the 
cycle duration. Key people are 
informed if any alarm occur 
during the cycle. The cycle print 
out is evaluated at the end of 
the cycle. 
  0 0 
No RISK no 
further test 
is required 
Applicable alarms 
suggested in R&D 
lyophilisation cycle 
development report. 
Sealing SE1 capping vials 
Poor sealing; Not 
properly seated 
stoppers 
Non integral-vial.   Human error   
Capper set-up per component 
configuration. IPC performed 
during capping 
  0 0 
No RISK no 
further test 
is required 
Container/closure 
integrity studies. 
Terminal 
sterilization 
TS1 
Batch 
Sterilization 
Product 
degradation 
Results OOS 
 
Autoclave 
malfunction  
During PPQ execution, after one 
batch filling, one tray of the 
product is sterilized twice. The 
rest of the batch is going to be 
sterilized according to approved 
product conditions.Samples are 
placed on stability after TS. 
 
0 0 
No RISK no 
further test 
is required 
R&D team studies the 
impact on Terminal 
sterilization on the 
product. 
100 % Particles 
inspection 
I1 Inspection Particles Batch failure 
 
Product degradation / 
Process related  
Automatic Inspection is 
performed in all batches  
0 0 
No RISK no 
further test 
is required 
All PPQ batches are 
inspected and after 10 
batches alert and action 
limits are set. 
Product storage STO1 
Product storage 
from inspection 
and packaging to 
shipment. 
Excessive 
exposure to 
light, 
temperature 
above or below 
the 
recommended 
range 
Reduced stability 
of product. 
  
Human error, failure 
to comply with 
storage conditions. 
  
Training of operators, 
instructions documented in 
batch record. Storage 
conditions verified in validation. 
  0 0 
No RISK no 
further test 
is required 
Stability studies. 
Photostability studies. 
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Also risk mitigation can simply reveal the most critical process steps that might impact CQA, as well as other tools described under Chapter 4 – 
PARAMETERS AND METHODS – Quality Risk Management Tools.Figure 50 exemplifies the use of this tool for an injectable product for a filtration process 
of a generic Hikma manufacturing process.  
Figure 50: Example of a risk assessment to be used in a process validation plan 
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2) Description of Process Controls and Process Characterization 
 
The information provided on the control strategy should include detailed descriptions of the 
individual elements of the control strategy plus, when appropriate, a summary of the overall 
drug substance control strategy. Particularly at the time that precedes the Process Performance 
qualification, it is important to describe in a detailed manner the process controls. 
 
 
 
 
 
 
 
 
 
 
 
During Product lifecycle this state of control is ensured also by Process Design space 
verification. In PV Guidance from 2011 it is stated “We recommend that a statistician or person 
with adequate training in statistical process control techniques develop the data collection plan 
and statistical methods and procedures used measuring and evaluating process stability and 
process capability”. 
 
 
 
Risk control 
 Description of Manufacturing Process and Process Controls 
 Control of Materials 
 Controls of Critical Steps and Intermediates 
 Container Closure 
 Control of Drug Substance 
 
 Risk acceptance  
 Risk reduction 
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a. The sampling plan is adequate (in-process controls are covering the CQA) 
 
The process validation sampling plan should be adequate to demonstrate 
sufficient statistical confidence of quality. One of the appropriate methodologies 
to design and analyse the process validation is a risk assessment tool (Table 
11). 
During PPQ the number of samples should be adequate to provide 
sufficient statistical confidence of quality both within a batch and between 
batches. The confidence level selected can be based on risk analysis since it is 
related with a particular attribute under examination. 
 
 Acceptance criteria for the sampling and testing conducted by the 
quality control unit shall be adequate to ensure that batches of 
drug products meet each appropriate statistical quality control 
criteria as a condition for their approval and release. The statistical 
quality control criteria shall included appropriate acceptance levels 
and/ or appropriate rejection levels. 
 Valid in-process specifications for such characteristics shall be 
consistent and shall be derived from previous acceptable process 
average and process variability estimates where possible and 
determined by the application of suitable statistical procedures 
where appropriate. 
 Examination and testing of samples shall assure that the drug 
product and in process material conform to specification. 
 Written records required by this part shall be maintained so that 
data therein can be used for evaluating, at least annually, the 
quality standards of each drug product to determine the need for 
changes in drug product specifications or manufacturing or control 
procedures.  
 
 
 
 
b. The system is capable 
 
 The lower bound of CPK confidence interval (Figure 23 and Figure 24) 
should be evaluated (tied to the adequacy of sampling plan) 
 Evaluate the criteria to analyse the process data 
o Expected data. 
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o If results are transformed, confirm if the specifications were 
transformed accordingly. 
o Analyse data collected under operating conditions in order confirm 
process stability. 
 Question: Can the process consistently make product that meets 
specifications? 
 Commonly used Statistical Tool: Process Capability Studies 
 Targets: 
o The demonstrated CPK ensures that Critical Quality Attributes 
(CQAs) are consistently met; 
o The CPK meets requirements of other steps in the process, 
particularly for in process data; 
o Remember, “The confidence level selected can be based on risk 
analysis as it relates to the particular attribute under examination”. 
 
 
c. The system is stable 
 
 Question: Can the process consistently make product that meets 
specifications? 
 Commonly used Statistical Tool: Control Charts. 
 Contrasting capability studies, time is taken into consideration. 
 Targets: 
o The system is stable under controlled conditions; 
o Activities are performed during commercial manufacturing to 
continually assure that the process remains in state of control; 
o Control limits do not exceed CQA specifications; 
o The variation is constant over the time; 
o As before, “The confidence level selected can be based on risk 
analysis as it relates to the particular attribute under examination”. 
 Points for consideration: 
o Does the system ensure consistent product, even with varying 
inputs? 
o Do finished attributes “drift” within specifications, or are they stable 
over time? 
o Is it a natural variation or special cause variation? 
o Do you see acceptable time based variation both within batches 
and between batches? 
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3) Design space (statistical tools and risk assessment) 
 
 
The figure above (part of Hikma QRM approach Figure 47) gives a high level of 
Quality by Design approach integrated in Risk approach. Knowledge of the quality 
target profile, a dynamic summary of the characteristics of a product to ensure the 
desired quality will drive the establishment of an adequate product specification, which 
will then lead process development and routine process improvements. The first 
criticality assessment goal is to brainstorm and document the rational through which 
variables should be studied in order to drive validation activities in a lean manner. To do 
this, it is necessary to prioritise the variables that may impact product CQAs throught 
the process, based on the perception of criticality using prior knowledge and past 
experience to quantify the impact. 
During the stage of process development and scaling-up, Design of Space 
approach may be useful to quantify the link between the CQA and CPP and or CMA by 
means of statistical tools. Establishing and quantifying this relationship will constitute 
the bases for the design space, a multi-dimensional space of input variables that 
provides assurance of quality.  
At this stage the process and the product should both be well characterised. 
While the design space will identify the feasible space, the normal operating ranges 
(NOR) should also be defined, i.e. the preferred operating spaces, considering 
performance aspects of the process, such as operational costs and process capability. 
Here, a formal risk assessment tool is applied, linkin process development and 
manufacturing. One possible methodology to apply is FMECA (e.g. Table 11) listing 
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again all possible failure modes that may occur when in commercial manufacturing. 
Then, the potential effects related with failure are listed. For such a purpose, actions are 
identified to find and eliminate potential causes, potential failure modes and effects or to 
increase the level of detection. 
The output of the risk assessment will feed the criticality analysis, where process 
parameters and material attributes are classified as critical or non-critical based on their 
impact on the final product`s CQAs. Critical parameters should be monitored and 
controlled to ensure that the process yields product with the desired quality. 
The level of effort in controlling a critical parameter should reflect not only the 
FMEA output, but should also take into consideration other aspects, such as the 
magnitude of the effect (sensitivity to changes of the parameter value), the location of 
the NOR relative to the design space, the closeness of the design space to the edge of 
failure and the robustness of the process with regard to those parameters, translated 
into the process capability index. 
The criticality will be a key driver for defining the process control strategy, through 
which the process will be kept in control throughout its lifecycle. This strategy should 
target the control of CMAs and CPPs to assure operation inside the design space and 
should also drive the continuous improvement and optimization of the process. 
Trending tools – like control charts and process capability analisys – and 
investigational methods, such as multivariate analysis, may flag special and common 
causes of variation coming from variability not addressed during development and can 
quantify the impact on CQAs, increasing process knowledge. Process changes driven 
by the continuous improvement programme can be implemented following adequate 
change control procedures.  
 
 
4) Risk Reviewed by Quality and Risk Communication  
 
Address the need to revisit the risk assessment at a point in the future  to take into account 
any new information/ experience  
 Determine an appropriate frequently  
 Purpose – what items will be reviewed 
 Communicating information with key groups  
 Understanding our risks and conveying them to others 
 
 
5) Cleared for distribution  
 
A Process Validation is the collection and evaluation of data, from the process designed 
stage and continuing through commercial production, which ensure that the manufacturing 
Chapter 5   RESULTS – Assess Products` Risk Framework 
93 
 
process including equipment, building, personnel and materials is capable of achieving the 
intended results on a consistent and continuous basis (Guidance for Industry - Process 
Validation: General Principles and Practices, January 2011). 
 
 
6) Continuous Product Verification  
 
 
 Every batch manufactured provides more data (also see Section 2.4.3 - 
Stage 3: Continued Process Verification (CPV)); 
 With more data, enhance process and product understanding; 
 It is the Hikma`s responsibility to update the following accordingly: 
o Specifications 
o In process or manufacturing controls 
o Sampling plans 
 
In order to assure that the process remains in a state of control (the validated state) during 
commercial manufacture, a robust system is required for detecting unplanned departures (drift) 
from the designed process, and there should be a strong emphasis on the use of statistically 
trended data, which should also be reviewed in a timely manner by trained personnel. 
The development of a Data Collection Plan can be written ensuring that the information 
collected can verify that the critical quality attributes are being controlled throughout the 
process. The quality unit should evaluate this data, discuss possible trends or drifts in the 
process, and coordinate any correction or follow-up actions with production personnel.   
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5.5 HIKMA CASE STUDIES – Risk Approach Implementation 
 
This chapter aims to give a general idea about simple concepts to assess products` risk 
framework and to elucidate the use of Hikma Quality Risk Management approach for types of 
Hikma injectable products.  
 
5.5.1 Aqueous solutions 
 
During monitoring of bulk solution IPC for a liquid product it was verified that the obtained 
ascorbic acid assay result was consistently in low end, between 0.63 and 065 mg/ mL, while the 
limits were 0.62 – 0.98 mg/ mL (70 – 110 %). Also pH results seem to follow a tendency, but in 
an inverse manner, i.e. when the ascorbic acid assay was lower, the pH was higher. The 
product formulation is API, water, Ascorbic Acid and NaOH used for pH adjustment. Ascorbic 
acid is added to the formulation in a concentration of 0.89 mg/ mL (with no overage). Due to the 
fact that a considerable quantity of ascorbic acid is lost until the end of bulk preparation, a 
mitigation process was started and the chosen method was RAMM (described under Section 
4.5.3 - Risk Analysis and Mitigation Matrix (RAMM)).  
RAMM method will clarify in which direction the process parameters impact CQAs and 
which quantity of these parameters affects the CQAs are critical for manufacturing excellence. 
And this understanding can be used to optimize the process, increase ascorbic acid and 
consequently end up with a more robust process or add appropriate control measures to adjust 
process to make on target product. 
Stage 1 – Team and Knowledge – The process was considered since materials weights 
and storage until the IPC sample is analysed. In total, more than 10 batches were initially 
supervised (before any action to control potential risk of ascorbic acid OOS assay) and ascorbic 
acid was also monitored to understand how process is run on a daily basis. Ascorbic Acid 
molecule properties were studied in order to collect information for risk analysis. Summing up 
Ascorbic acid has pKa values of 4.2 and 11.6. As a mild reducing agent, ascorbic acid degrades 
upon exposure to air, converting the oxygen to water. The redox reaction is accelerated by the 
presence of metal ions and light. It can be oxidized by one electron to a radical state or doubly 
oxidized to the stable form called dehydroascorbic acid. 
 
Stage 2 – Identifying the CQAs – The desired CQAs are in this case the ascorbic acid assay, 
pH and density of the intermediate product - bulk solution. 
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- Higher Criticality is Ascorbic Acid Assay and it should be the focus of the risk 
assessment; therefore its importance was scored with 9. 
- Medium Criticality is pH (limits pH 8.5 – 9.1) as there was a possibility to contribute for 
the variation in study; it was scored with 3. 
- Low criticality is Density of bulk solution (1.0094 – 1.0196 g/ cm
3
), anyhow it is part of 
In-process-controls for the bulk solution and it should be the focus of the risk 
assessment; therefore its importance was scored with 9. 
 
Stage 3 – Definition the Process Steps – Weighing of raw-materials and bulk solution 
manufacturing. 
Stage 4 – Definition of Process and Material – The process steps were broken down into 
process parameters.  
Stage 5 – RAMM construction and Scores – The RAMM uses a matrix of process input 
factors and quality attributes to assess risk and impact (Table 12). Some of Process became 
critical process parameters and other important parameters. 
Likewise, the matrix can be filtered to determine which process step or input factors had 
the greatest impact on a particular attribute. 
 
Table 12: Risk of citric acid losses during compounding mitigation 
  Relative importance of 
CQA (Bulk IPC) 
9 3 1 
TOTAL 
Process step Class 
Process Parameters  
A
s
s
a
y
 (
C
it
ri
c
 a
c
id
) 
IP
C
 
p
H
 
D
e
n
s
it
y
 
Weighing Raw-
materials 
Procedure 1 
 Weigh API, Ascorbic 
Acid and HCl  
1 1 1 1 
Weighing Raw-
materials 
Procedure 2 
Ascorbic Acid batch time 
since the first time 
container was opened 
(contact with light and 
oxygen) 
3 1 1 3 
Compounding Personal 1 Equipment cleaning 1 1 1 1 
Compounding Procedure 3 
Prepare HCl 1 N solution 
for pH adjustment 
3 9 1 27 
Compounding Procedure 4 WFI addition 1 1 1 1 
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  Relative importance of 
CQA (Bulk IPC) 
9 3 1 
TOTAL 
Process step Class 
Process Parameters  
A
s
s
a
y
 (
C
it
ri
c
 a
c
id
) 
IP
C
 
p
H
 
D
e
n
s
it
y
 
Compounding Procedure 5 
WFI sparging with 
nitrogen 
9 1 1 9 
Compounding Procedure 6 Ascorbic acid addition 9 9 1 81 
Compounding Procedure 7 
1
st
 pH adjustment (6.8 – 
7.2) (WFI+ Ascorbic Acid) 
9 9 1 81 
Compounding Procedure 8 1
st
 API portion addition 1 1 3 3 
Compounding Procedure 9 
2
nd
 pH adjustment (WFI + 
API) 
9 9 1 81 
Compounding Procedure 10 2
nd
 API portion addition 1 1 3 3 
Compounding Procedure 11 
3
nd
 pH adjustment (time 
and mixing speed 
variable) 
9 9 1 81 
Compounding Procedure 12 3
nd
 API portion addition 1 1 3 3 
Compounding Procedure 13 
4
nd
 pH adjustment  (time 
and mixing speed 
variable) 
9 9 1 81 
Compounding Personal 14 
Quantities added of 
NaOH at once 
    
Compounding Procedure 15 
Solution sparging with 
nitrogen 
9 1 1 9 
Compounding Procedure 16 Bulk solution final volume 1 3 9 27 
Sampling Procedure 17 
Sampling overlaid with 
nitrogen 
9 1 1 9 
 
 
The above matrix related the CQA – Ascorbic acid assay – with most CPPs as nitrogen 
sparging and pH adjustments. At this stage the RAMM can be sorted and filtered so that 
process inputs can be assessed by their impact on a specific response, by the interim process 
step, or for their overall impact on the entire process.  
 
The process procedure was revisited with particular attention to nitrogen sparging steps 
and pH adjustments. The following risk observations were made: 
- WFI is purged with nitrogen until Dissolved Oxygen (DO) ≤ 0.5 ppm, and only after Q.S. the 
bulk solution is again purged until DO ≤ 0.5 ppm;  
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- After ascorbic acid addition and until final Q.S. the preparation has no steps to perform 
nitrogen purging; 
 
- During agitation/ dissolution of ascorbic acid in the preparation container (opened container) 
the DO increases quickly for more than 3 ppm and continues to increase during the API 
additions and the adjustments; 
- During addition and dissolution of the 4 API portions and pH adjustments to pH 9.0, which 
takes around 1 hour, the preparation container is kept opened and the mixing has to be strong 
in order to dissolve the API leading to incorporation of air into the solution; during these steps 
there is no nitrogen overlaying; 
- After last step of nitrogen purging to achieve DO ≤ 0.5 ppm, the nitrogen is turned off and the 
samples are collected while the solution is mixed leading again to incorporation of air into the 
solution; 
- WFI to bring the volume to 98 % and then to 100 % is not previously sparged with nitrogen; 
- No nitrogen overlaying is performed to the sampling containers; 
- Bulk solution is not protected from light during compounding. 
- The pH during adjustments after API addition increase for a small instant to pH 12 [one pka of 
ascorbic acid is 11.6]; immediately after the pH decreases while the API (acidic) is dissolving. 
API dissolves at approximately pH 9.00.  
 
Improvements were immediately implemented to the compounding process, as follows: 
 
- Additional step for purging the solution with nitrogen after ascorbic acid addition (and 
during pH adjustment to 6.8 – 7.2) until just before API addition; 
- Overlaying the bulk solution with nitrogen during all four pH adjustments after API 
addition; 
- WFI to bring the volume to 98 % and then to 100 % is previously sparged with nitrogen; 
- After final purging step (after Q.S. and final homogenization)  there are no advantage in 
keep mixing the solution (the solution is homogenous),  the samples should be collected 
without agitation; 
- Due to the impossibility of overlaying the sampling bottles with nitrogen, the containers 
should be filled until the top and in this way avoid oxygen headspace that can react with 
ascorbic acid; 
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-  pH was kept under 9.5 during all pH adjustments; fixed portions (600 – 800 mL) of 
NaOH  1M solution have to be added slowly to the solution ; 
- Agitation speed is controlled in order to be enough to achieve proper dissolution but not 
too vigorous  to allow high oxygen incorporation into the solution; 
- While waiting IPC results the solution is overlaid with nitrogen and the container sealed.  
 
 
The obtained results for ascorbic acid assay, after the implementation of these controls and 
procedures into the compounding process, were between 0.82 – 0.84 mg/ mL (IPC specification 
0.62 – 0.98 mg/ mL). 
 
5.5.2 Oils 
 
During a manufacturing campaign for three batches of an oil basis product at Hikma, 
differences in terms of API assay were found in bulk solution IPC. The results were within 
specification but the drift inter-batches predict some uncontrolled parameter. The main focus of 
process verification was the compounding of bulk solution and the assays of all batches 
compounded before in order to distinguish any trend (recently or since the product was 
commercialized). 
 
 
Figure 51: IPC assay for bulk solution of produced batches for an oil basis product.  
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Evaluating the above graphic that  plots the data for IPC API assay results for 35 batches, 
no trend was observed. The variation was considered controlled since has a consistent pattern 
over time and the process seems to be operating within the bounds of the control limits of 95.0 
% to 105.0 %. However, the Gass Curve is dislocated for the upper limits as the average is 
102.1 %. This average limit indicates that some procedure or parameter could be working 
randomly. An investigation was iniciated and Hikma risk assessment (Appendix Table-A 1) was 
applied for weighing materials process step and compounding process step. 
 
Figure 52: Hikma risk assessment tool applied for this Oil case – Priority RISK: Transfer liquid RM with high viscosity 
into the preparation tank – “High RISK further tests and controls required” 
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Figure 53: Graph showing the criticality levels for the studied process steps. 
 
According to the calculated criticality the critical obtained procedure is “Transfer liquid RMs 
with high viscosity” (Figure 53). Also RPN were calculated and it was concordantly high (equal 
to 125) (Figure 54). A question was raised: Can the trend of high assay results be correlated 
with the incorrect addition of viscous liquids to the tank? The procedures were evaluated. Since 
this compounding process (was originally a tech transfer process for a client) it has no need for 
q.s. and all added raw-materials are previously weighted, it might have a huge impact on final 
volume/ weight but it had been never verified.  
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  Figure 54: Graph showing the RPN results for the studied process steps. 
Three bulk solutions prepared by different operators were supervised. The first component 
added to the preparation tank is an oil and this initial quantity of oil is directly weight in the tank. 
The 2
nd
 raw-material added to the preparation tank is a very viscous liquid, previously weight in 
4 containers and added directly to the preparation tank. An improper transference of this 
viscous excipients (oil basis) was performed by all operators. The totality of the this excipient, 
which was divided into 4 containers, could not be transferred to the preparation tank due to its 
high viscosity and limitations from maximum compounding time to wait until all oil is poured out 
from each container into the preparation tank. 
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Due to the fact that the batch size is only 30 L, it was concluded that the 2 % (in average) 
more concentrated solution is due to this loss of this viscous excipient. Around 600 mL of oil 
were not added to the tank and because the final batch was not weigh, this was not noticed. 
 
The following measures were implemented:  
 
- Preparation tank is tared on the floor scale and the weights of every raw-material are 
double checked. 
- In particular, this viscous excipient is weight in the tank in addition to the 1
st
 excipient 
that was already weighted initially in the tank. 
- The final weight is confirmed and the floor scale print out has to be added to the batch 
record. 
 
 
Figure 55: IPC assay for bulk solution of produced batches for an oil basis product – after controls had been 
implemented to the compounding process.  
 
After all these controls had been implemented, the IPC API assay results obtained from 
batch monitoring indicates results between 99.9 % e 101.2 % and a RSD of 0.7 % (Figure 55). 
 
 
5.5.3 Lyophilized Products 
 
The main purpose of Lyophilization process is to alleviate the effect of water content on 
finish product and over product shelf-life and keep its Quality Attributes as liquid bulk but in a 
stable form (powder) for longer time. Normally lyophilized products are very sensitive to heat 
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light and oxygen, and accordingly the more stable product form is powder. Therefore this case 
study will focus on the risk control of the process parameters which may directly or indirectly 
contribute to the alteration of CQAs of Finish Product. 
Additionally to water content, temperature plays a key role along manufacturing process, 
namely during lyophilisation cycle. Combination of Temperature and Water content influence 
two critical Product Quality Attributes driving Lyophilization Process Design and Validation:  
- Purity 
- Solubility 
Table 13: Process Parameters that might impact CQAs – Purity and Solubility 
Process Paramaters  
(influence of water 
content) 
Impact on CQAs 
Purity of finished product Solubility/reconstitution time 
Lyophilisation cycle 
and water content 
Once lyophilisation cycle is initiated as 
the solution is frozen, any availability of 
water on liquid form is likely to 
compromise severely the quality of the 
product on regards to purity. 
In extreme situations, if the water 
content reaches a certain point, melt 
back phenomena can occur. 
The availability of water during 
the lyophilisation cycle 
influences structural formation of 
the crystals which has direct 
impact on product solubility. 
This effect can be detected at 
time zero after lyophilisation or 
detected during shelf life. 
 
Water content  on 
finished product 
Water content of finished product 
typically affects product purity by 
promoting degradation over shelf life. 
The optimal percentage of water content 
is product dependent, however, for the 
majority of products the quality/stability 
increases with the decrease of water 
content. 
Water content of finished 
product influences severely the 
solubility of finished product. 
This effect can be detected at 
time zero or detected during 
shelf life.  
Temperature during 
lyophilisation cycle 
Affects directly product stability  
Influences structural formation of 
the crystals which has direct 
impact on product solubility 
 
Although, the temperature and water content seems to be controlled for initial Product 
Performance Quality during filling and lyophilisation processes, slightly changes might occur 
with high impact to the CQAs for these very sensitive (lyophilized) products. For these reasons, 
a continuous process verification and a dynamic control strategy in extremely important 
lyophilized products. Based on this a design space for CPPs must be carefully studied and 
challenge. 
Chapter 5   RESULTS – Assess Products` Risk Framework 
104 
 
Table 14: CPPs that impact purity and solubility (CQAs) in Finished Product 
Water content – critical 
in-process attribute 
CPPs 
Water effect as bulk 
solution 
- Time from compounding until 
freezing. 
Water content during 
lyophilisation cycle 
- Freezing temperature 
- Primary drying temperature, ramp 
profile and duration 
- Condenser capacity vs batch size 
- Fill volume (influencing cake height) 
- Secondary drying temperature and 
duration 
Water content of 
finished product  
during shelf life 
- Water content achieved at time zero 
- Residual moisture reabsorbed  from 
rubber stoppers 
 
  
The design space is studied in lab scale and the NOR for each Critical Process Parameter 
is verified to comply with final specifications set. During a pilot batch the proven acceptable 
range is challenged in order to confirm that the designed process is suitable for routine 
commercial manufacturing that can consistently deliver a product within specifications. After that 
a proposed range for commercial scale is set in order to start production of PPQ batches. For 
this case study the parameters and controls are described below in Figure 13. 
 
 
Before the production of PPQ batches of an Hikma product “B” extremely sensitive to heat 
and moisture (water content in finish product increases impurity “H”), the following Table 15 was 
design to ensure the correct and needed controls to the process, and showing that the Primary 
drying step should be determined for each cycle by a pressure rise test.  
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Table 15: Continuous Process Verification approach for a Lyophilized Product 
Factor 
PARAMETERS  
(or ATTRIBUTES) 
Range studied 
(lab scale) 
Actual data for the 
exhibit batch (pilot 
scale) 
Proposed range for 
commercial scale Θ 
Proposed 
Control 
(can change 
during batches 
comparison and 
monitoring) 
Lyophilization Process In-Process Controls (TESTING) 
  
Impurity “H” ∆ NMT 0.5 % 
Water content ∆ 0.3 – 1.5 % 
Reconstitution time ∆ NMT 1 min 
Product Drying (cycle) Process Parameters Controls 
Specifications 
(TESTING) 
Freezing 
Shelf temperature set point (-50) – (-55) °C -55 °C -55 °C 
To ensure all lyo 
CQAs (assay, 
water content, 
reconstitution 
time, RS content) 
Step duration ∆ 6 - 8 hours 7 hours 7 hours 
Primary 
drying 
Shelf ramp to primary 
drying 
1 - 3 °C/min 2 °C/min 2 - 3 °C/min 
Shelf temperature ∆ 20 - 30 °C 25 °C 20 - 30 °C 
Shelf temperature set point 25 °C 25 °C 25 °C 
Step duration ∆ 15 - 19 hours 17 hours 
to be determined 
based on the 
pressure rise test 
Chamber pressure 
0.001 - 0.01 
mbar 
0.005 - 0.009 mbar 0.001 - 0.01 mbar 
Chamber pressure alarm 0.03 mbar 0.03 mbar 0.03 mbar 
Secondary 
drying 
Shelf temperature ∆ 30 - 40 °C 35 °C 30 - 40 °C 
Step duration ∆ 7 - 9 hours 8 hours 8 hours 
Product Drying (cycle) In-Process Controls (Product) 
Primary drying Time  17 hours ± 2 hours 
Product Temperature 20  ± 10 °C 
 
KEY for DESIGN SPACE 
VERIFICATION             
∆ 
Critical input material attributes (CMA), critical process parameters (CPP) or critical quality atributes 
(CQA) of in-process material or final drug product 
Θ The proposed operating ranges for commercial scale will be qualified and continually verified 
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5.5.4 Suspensions 
 
The last Hikma case study was an injectable suspension “BetaM” which had a variable 
particle sizes even though with specification. Also, the density of in finish product was near the 
lower limit. 
 
a) Particle size (CQA) variation 
 
The first step was to understand how particle size distribution changed over the 
last produced batches. The study was started through a detailed analysis of product 
development where it was clearly specified that the suspension could be unstable 
above 20 °C. This was an indication that temperature was playing a role on particle 
sizes variation. 
 
 
Figure 56: Unstable size change for suspension “BetaM” 
 
 
Figure 57: Particle sizes of the last produced Suspensions “BetaM”. 
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Based on the analysis of Figure 57, it was concluded that the variation of temperature over 
the years could influence the differences of particle sizes. Therefore, it was decided to control 
the filling temperature at 18 ºC.  It is expected that the unstable suspension (Figure 57) become 
a stable size suspension (Figure 58). 
 
Figure 58: Stable size change for suspension “BetaM” 
 
b) Density (CQA) variation 
The second step was to understand what could be the causes for density variability. For 
one of the batches a PHA worksheet was given to the operators to describe possible risks 
during aseptic filling. This applies for operators’ prior experience or knowledge of hazard to 
identify future hazards, hazardous situation. 
 
Table 16: PHA worksheet for a suspension with low density results 
System: Suspension Operating mode: Aseptic filling Analyst/Date: 
07.10.2013 
Product Hazard 
Accidental 
event  
 
(what, where, 
when) 
Probable 
causes 
Contingencies / 
Preventive 
actions 
Probability Severity Comments 
“BetaM” Insuficient 
mixing 
speed 
Not 
homogeneous 
solution in the 
validated 
mixing speed 
range 
Tank 
equivalence 
assumption 
(differed tank 
from the one 
used in initial 
PPQ 
batches) 
Validated the 
mixing speed for 
the product 
during filling 
high high PPQ speed 
(CPP) and 
density (CQA) 
have to be 
performed 
 
A PPQ plan was written and three PPQ batches were compounded and filled in sterile 
room with the current tank. Samples filled at 3 different speeds (one from each batch) were 
collected and density was analysed. It was confirmed an insufficient agitation speed before this 
risk analysis and the new range for mixing speed was implement.  
 
In conclusion, with both CPPs (mixing speed and filling temperature) controlled, the 
process was considered in state of control.   
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Chapter 6 GENERAL DISCUSSION 
 
The industry has moved into taking a risk based approach to validation and this makes 
perfect sense; adopt a proficient risk management methodology, identifying risks and avoiding 
building uncontrolled manufacturing processes. Along with the new guidelines, the repetition of 
process qualification and product lifecycle validation phrases illustrates that this is a complete 
new world from now on. In order to support the new requirements, the suggested Hikma risk 
approach for process validation promises to minimize process risk and ensure the required 
confidence prior to distribution of the product. 
An important objective of this thesis was the possibility to give Hikma a perspective to 
implement process validation over product lifecycle. The suggested quality risk management 
system, based on the latest FDA guidelines, demonstrates that the combination of process 
parameters and material attributes established at pilot scale during pharmaceutical 
development are capable of delivering an appropriate quality product on a commercial scale. 
With the work developed in this thesis it is aimed that the state of manufacturing in Hikma gains 
an extensive knowledge about critical product and process parameters and quality attributes of 
its products. Following this line of manufacturing, Hikma strive for continuous improvement. 
The scientific and data driven process suggested by Hikma risk approach will reduce 
subjectivity, quantitative as well as qualitative assessment will assess process risks. This 
approach will allow risks prioritization and controls risk to an appropriate and acceptable level. 
The valuable general Risk Assessment for Hikma injectable products created will assess 
products’ risk framework and enable the design of process validation plan based on a scientific- 
and risk based approach. A risk approach for process validation it does not mean doing less, 
but doing the right amount at the right time and avoiding non-value added activities as well as 
missing any crucial validation activity.  
The risk-based approach discussed is based in statistical tools, and in a scientific manner 
elucidate the appropriate methods to evaluate risks and process variability. With continued 
process monitoring and studying trends over time, Hikma may be able to discover real problems 
early enough to prevent process failures, product losses, and expensive mistakes. 
 In order to make more efficient and resourceful the application of risk approach and to 
facilitate the evaluation of new and existent products at Hikma, statistical and risk tools had 
been described and studied. The summary of common statistical and risk tools described in this 
thesis should support the risk approach. However, none of the defining, evaluating, trending, 
and monitoring described in this thesis and the strategy for design space verification can occur 
without knowledgeable analytical personnel using dependable equipment to perform robust and 
reproducible laboratory methods behind manufacturing scenes.  
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The bottom line is to consider that people see things from different angles – and quite 
rightly also. The more time spend up front on the risk assessment means that validation effort is 
reduced and usually more robust to go with it. In this way Hikma relies upon the manufacturing 
controls and standards to ensure that time and time again, lot after lot, year after year the same 
clinical profile will be delivered because the product will be the same in its quality. By assuring 
the conformity of all the parameters of the manufacturing process, we may guarantee at the end 
that the product has the expected quality. Moreover, ongoing process verification optimizes a 
validated process. 
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Chapter 7 CONCLUSIONS 
 
In conclusion the way Raw-materials CQA and a variety of parameters are related with 
Finished Product CQA must be capable of delivering a product of appropriate quality on a 
commercial scale. This study aimed to present a risk-based approach to evaluate the scope of 
process validation activities in Hikma. Through the use of the risk tools, an objective 
assessment of potential uncertainties and their effect on products` critical quality attributes were 
evaluated and organized to make the most optimal decisions. Furthermore, the described 
approach risk-based also provided a consistent methodology for decision making which was 
easily aligned with Hikma goals such as resources allocation and ensuring patient safety and 
quality products; by building quality into processes and consequently into products. Ultimately, 
through the consistent use of statistic tools to monitor the variation and maintain processes in 
state of control along product lifecycle, the number of surprises and their impact will be 
minimized. The goal of this work was achieved. Assess to products´ risk framework will be 
provided to production teams during Process Performance qualification and over products 
lifecycle based in scientific rational by using recognized language, structure and tools. 
Certainly, the work described in this thesis has provided additional insights into what is 
already known about Injectables Manufacturing Process Validation based on Risk Assessment 
in Hikma Farmcêutica Portugal S.A. and Thymoorgan Pharmazie GmbH. Optimization and 
improvement of Hikma risk based tools, methods of analyses and procedures will lead the 
company to higher levels of quality and compliance.   
It is becoming increasingly clear that a continuing improving and implementation of this risk 
management tools is essential to accomplish FDA requirements and to compete at a very high 
quality level assuring at the same time efficient processes.  
Process Validation is a transitioning from a check-box activity to value-added. There is 
interplay between raw-materials, process parameters, controls, and final outcomes (drug 
products). A systematic approach that emphasizes product and process understanding and 
process control, based on scientific operations and quality risk management is the key for 
innovation and continual improvement. 
Concluding, validation is a lifecycle which is living and breathing, it has matured with age 
and doesn`t have to be cumbersome anymore.  
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Chapter 8 FUTURE PERSPECTIVES 
 
In a near future design space limits as other process parameters limits can be challenge 
with computational simulations and a specialized team should be trained in simulators software 
and be extended to Risk Management system for other Hikma medicines forms – syrups, 
tablets, sprays solutions, capsules, suspensions, etc. 
Moreover, it is almost impossible to achieve the FDA requirements, concerning to ensure 
uniform collection and assessment of information about the process in product lifecycle, without 
using a software platform in order to access information quickly throughout the product lifecycle. 
It is necessary a Validation Lifecycle Management system in order to access, aggregate, 
analyze, and understand the data generated. With this system, Hikma could provide report data, 
on demand and in meaningful context, such as a report that allows a combination with PAT 
approach correlating upstream parameters with downstream process outcomes (automatically 
accounting for batch genealogy) during both process design and commercial operations.   
Within the same system, users should be able to define the risk levels for each of the key 
factors; severity, likelihood of occurrence, and detectability, in a similar way as it was designed 
this Hikma risk approach. The system would automatically calculate the risk class and risk 
priority. Based on the risk, users could effectively build appropriate testing to test the degree of 
variation to mitigate those risks. 
The leveraging data in the right way can enable greater Process Intelligence, which assists 
with control variability and quality improvements and results in higher yields and accelerates the 
time to market. 
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Table-A 1: Risk Assessment applied to the oil case study – Process Phases: Weighing and Compounding 
Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on 
Entire System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probabili
ty of 
Occurren
ce 
Risk Reduction and Risk 
Evaluation/Process 
Controls 
(D) 
Probabili
ty of 
Detectio
n 
Critical
ity 
RPN 
value 
CONCLUSION 
Validation/ Verification 
STUDY to be done 
Manufacturing 
Process Phase 
Identification 
of Process 
Step 
Phase to 
which 
belongs the 
process step 
RISK 
Probable 
consequences 
/ OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 5 
high] 
Incorrect INPUTS 
From 1 
to 5 
[1=rare; 
5 
frequent] 
Variability Control 
From 1 
to 5 
[1=high; 
5 low] 
S x O SxOxD Step Risk 
Additional Controls / 
Tests to be implemented 
during Process 
Validation 
warehouse/ 
preparation 
for 
compounding 
W1 
Weighing of 
API 
Incorrect weight. 
Low or high 
assay results 
(OOS bulk 
IPC); batch 
failure. 
5 
Wrong calibration 
of the scales. 
Human error during 
weighing.  
1 
IPC assay (fill volume 
adjustment in order to 
compensate the 
difference on potency). 
Scales are calibrated 
daily. All weights are 
triple verified by both 
compounding operators 
and QA. 
4 5 20 
Low RISK 
further test to 
be evaluated 
Comparation of Hikma 
CoA results with 
Supplier CoA results in 
order to confirm the 
results are aligned.  
W2 
Weighing of 
Excipients 
Incorrect weight. 
Bulk solution 
IPC OOS. 
Finished 
Product OOS. 
Reduced 
stability. 
2 
Wrong calibration 
of the scales. 
Human error during 
weighing.  
1 
Scales are calibrated 
daily. All weights are 
double verified by both 
compounding operators 
and QA. 
5 2 10 
No RISK no 
further test is 
required 
Controlled conditions to 
weight hygroscopy raw-
materials. Low 
ventilation to weight 
light and fluffy powders. 
W3 
Raw-
Materials  
storage 
(sensitivities) 
Raw-materials 
not overlayed 
with nitrogen; 
Not protected 
from light; not 
stored under 
appropriate 
conditions 
Raw-materials 
degradation 
(high content 
of impurities) 
and decrease 
of potency 
3 
Human error 
(storage conditions 
not followed); If 
raw materials is not 
kept in the original 
container until 
production day. 
3 
All Raw-materials are 
sampled under laminar 
flow and the top of the 
containers overlayed 
with Nitrogen; here are 
specific instructions in 
SOPs and batch records 
5 9 45 
Med RISK 
further test 
required 
Raw-materials included 
in SOP compiling the 
conditions for the 
weighing 
W4 
API 
calculation to 
adjust 
potency 
Added amount of 
API is higher or 
lower than 
required 
Low or high 
assay results 
(OOS bulk 
IPC); batch 
failure 
5 
API assay, Water 
content or Solvents 
wrongly reported in 
the CoA used for 
calculations; 
Human error in 
calculations 
1 
Calculation of API is 
double verified bedsore 
weighing and recorded 
in the MBR.  All weights 
are double verified by 
both compounding 
operators and QA. 
1 5 5 
No RISK no 
further test is 
required 
Formulas for API 
calculation adjustment 
revised by Quality Unit 
Director or QC Manager 
at the moment of Batch 
records approval 
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Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on 
Entire System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probabili
ty of 
Occurren
ce 
Risk Reduction and Risk 
Evaluation/Process 
Controls 
(D) 
Probabili
ty of 
Detectio
n 
Critical
ity 
RPN 
value 
CONCLUSION 
Validation/ Verification 
STUDY to be done 
Manufacturing 
Process Phase 
Identification 
of Process 
Step 
Phase to 
which 
belongs the 
process step 
RISK 
Probable 
consequences 
/ OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 5 
high] 
Incorrect INPUTS 
From 1 
to 5 
[1=rare; 
5 
frequent] 
Variability Control 
From 1 
to 5 
[1=high; 
5 low] 
S x O SxOxD Step Risk 
Additional Controls / 
Tests to be implemented 
during Process 
Validation 
Compounding 
C1 
Initial WFI / 
oil / liquid 
excipient 
weighing in 
the 
compounding 
tank 
Incorrect weight. 
Low or high 
assay results 
(OOS bulk 
IPC); batch 
failure. 
5 
Wrong calibration 
of the scales. 
Human error during 
weighing.  
3 
Scales are calibrated 
daily. All weights are 
double verified by both 
compounding operators 
and QA. 
3 15 45 
Med RISK 
further test 
required 
N/A 
C2 
DO in bulk 
solution (or 
initial 
solution 
purged with 
filtered 
Nitrogen) 
Oxygen content 
higher than x 
mg/ L 
API 
degradation. 
Preservatives 
(if present) 
that reduce 
the reactive 
oxygen in 
solution are 
consumed 
immediately. 
Reduced 
product 
stability. 
1 
Oxygen sensor 
malfunction. 
Human errors (high 
mixing speed allow 
oxygen in the 
solution; tank not 
closed after 
purging) 
1 
Control of DO in solution 
using an oxygen sensor 
daily calibrated. 
1 1 1 
No RISK no 
further test is 
required 
Oxygen sensitivity and 
stability studies for 
different headspace 
oxygen percentages. 
C3 
Dissolution of 
API 
Insufficient 
mixing time and/ 
or speed; or over 
mixing 
Incomplete 
dissolution of 
API; Bulk 
solution does 
not need IPC 
specifications 
5 
Human error; 
incorrect visual 
evaluation of 
dissolution 
3 
Mixing speed in vortex is 
evaluated during all PPQ 
batches in order to 
validate a range. 
Samples are taken from 
the bottom for visual 
check of API dissolution. 
4 15 60 
Med RISK 
further test 
required 
Closely monitored 
during validation studies 
(time and mixed speed) 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on 
Entire System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probabili
ty of 
Occurren
ce 
Risk Reduction and Risk 
Evaluation/Process 
Controls 
(D) 
Probabili
ty of 
Detectio
n 
Critical
ity 
RPN 
value 
CONCLUSION 
Validation/ Verification 
STUDY to be done 
Manufacturing 
Process Phase 
Identification 
of Process 
Step 
Phase to 
which 
belongs the 
process step 
RISK 
Probable 
consequences 
/ OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 5 
high] 
Incorrect INPUTS 
From 1 
to 5 
[1=rare; 
5 
frequent] 
Variability Control 
From 1 
to 5 
[1=high; 
5 low] 
S x O SxOxD Step Risk 
Additional Controls / 
Tests to be implemented 
during Process 
Validation 
C4 
Foam 
formation 
during mixing 
for raw-
materials 
dissolution / 
sparging with 
filtered 
nitrogen 
Flow rate of 
nitrogen sparging 
is high or mixing 
speed is high. 
Product 
(foam) comes 
out from the 
tank; high DO 
with no 
possibility to 
continue 
sparging; 
visual 
confirmation 
of raw-
materials 
dissolution is 
impossible. 
Bulk IPC OOS, 
1 
Human error; 
insufficient 
monitoring of batch 
preparation 
1 
Products forming foam 
are compounded in 
bigger tanks size than 
the set batch size. 
Nitrogen overlay helps 
to control the foam. 
1 1 1 
No RISK no 
further test is 
required 
Prior to PPQ confirm the 
possibility of bulk 
solution forms foam; 
and design the process 
with an appropriate tank 
size for compounding 
accordingly 
C5 
Product light 
protection 
tank entrance 
not closed or 
covered with 
aluminium foil 
between raw-
materials 
addition 
API 
degradation.  
Reduced 
product 
stability. 
1 Human error. 2 
Operators are trained in 
product specificities and 
sensibilities. No other 
controls are 
implemented. 
2 2 4 
No RISK no 
further test is 
required 
Photostability studies. 
C6 
Dissolution of 
Excipients 
Insufficient 
mixing time and/ 
or speed; or over 
mixing 
Incomplete 
dissolution of 
API; Bulk 
solution does 
not meed IPC 
specifications 
4 
Human error; 
incorrect visual 
evaluation of 
dissolution. 
4 
Mixing speed in vortex is 
evaluated during all PPQ 
batches in order to 
validate a range. 
Samples are taken from 
the bottom. 
4 16 64 
Med RISK 
further test 
required 
Reference time for 
mixing of excipients in 
development report.  
Industrial mixing times 
and speeds for specific 
batch in specific tank 
detailed in Validation 
Report. 
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RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on 
Entire System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probabili
ty of 
Occurren
ce 
Risk Reduction and Risk 
Evaluation/Process 
Controls 
(D) 
Probabili
ty of 
Detectio
n 
Critical
ity 
RPN 
value 
CONCLUSION 
Validation/ Verification 
STUDY to be done 
Manufacturing 
Process Phase 
Identification 
of Process 
Step 
Phase to 
which 
belongs the 
process step 
RISK 
Probable 
consequences 
/ OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 5 
high] 
Incorrect INPUTS 
From 1 
to 5 
[1=rare; 
5 
frequent] 
Variability Control 
From 1 
to 5 
[1=high; 
5 low] 
S x O SxOxD Step Risk 
Additional Controls / 
Tests to be implemented 
during Process 
Validation 
C7 
Preparation 
Holding time 
Excessive hold 
time from the 
API addition to 
the end of 
compounding / 
beginning of 
lyophilisation 
cycle OR if 
volatile 
excipients in 
formulation (e.g. 
ethanol) long 
holding times for 
preparation will 
reduce their 
content in 
solution  
Increase of 
impurities 
3 
Product is not 
stable for long time 
in liquid state. 
Human error, 
mechanical 
problem in the line 
can lead  to 
exceeding the bulk 
holding time. 
2 
All critical times have to 
be studied and 
documented in the 
batch record. Solution is 
stored in sealed tank. 
1 6 6 
No RISK no 
further test is 
required 
Maximum holding time 
between API addition 
and beginning of 
freezing  phase to be 
evaluated for lyophilized 
products 
C8 
 Heating or 
cooling the 
solution 
Temperature 
above or below 
the set limits 
Increase of 
impurities. 
Dissolution 
difficulties 
4 
Human error, 
mechanical 
problem (in chiller 
or heater) 
1 
Temperature limits for 
applicable steps are 
written in the batch 
records and are double 
check by 2 compouding 
operators. 
1 4 4 
No RISK no 
further test is 
required 
Or  for liquid products - 
Maximum holding time 
between API addition 
and end of filling. 
C10 
Liquids 
excipients 
with high 
viscosity 
Not totally 
transferred to 
preparation tank 
Low or high 
assay 
(compromise 
the batch) 
5 Human error 5 
If these liquids are not 
weight directly in the 
preparation tank, there 
are other actions as 
mechanical removal 
with WFI or container 
wash with bulk solution 
from the compounding 
tank (if not removed 
with another organic 
solution) 
5 25 125 
High RISK 
further tests 
and controls 
required 
Weighing procedures 
adjusted to different 
materials viscosities in 
order to reduce losses 
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Manufacturing Process Parameters and Consequences of Failure 
RISK ASSESSMENT / RISK REDUCTION  
FMECA - Failure Mode Effects and Criticality Analysis 
Process Phase  ID nr. Process Step 
Potential 
Variation 
Effect on 
Entire System 
(S) 
Severity 
(Level of 
Risk) 
Cause of Failure 
(O) 
Probabili
ty of 
Occurren
ce 
Risk Reduction and Risk 
Evaluation/Process 
Controls 
(D) 
Probabili
ty of 
Detectio
n 
Critical
ity 
RPN 
value 
CONCLUSION 
Validation/ Verification 
STUDY to be done 
Manufacturing 
Process Phase 
Identification 
of Process 
Step 
Phase to 
which 
belongs the 
process step 
RISK 
Probable 
consequences 
/ OUTPUTS 
Failures 
From 1 
to 5 
[1=low; 5 
high] 
Incorrect INPUTS 
From 1 
to 5 
[1=rare; 
5 
frequent] 
Variability Control 
From 1 
to 5 
[1=high; 
5 low] 
S x O SxOxD Step Risk 
Additional Controls / 
Tests to be implemented 
during Process 
Validation 
C11 Final Q.S. 
Human error; 
balance 
malfunction 
Low or high 
assay 
(compromise 
the batch) 
4 
Human error, scale 
malfunction 
2 
Balance is calibrated and 
verified prior to each 
compounding as per 
SOP. The Q.S. is double 
verified. 
1 8 8 
No RISK no 
further test is 
required 
Quantify the water 
amount to be added to 
the final Q.S. 
C12 Tank Transfer 
Product losses; 
Contamination; 
materials 
incompabilities 
Bioburden 
OOS;  High RS 
content 
3 Human error. 4 
All tanks are cleaned 
and sterilized using 
validated procedures. 
The compatible 
materials with product 
are described in the 
batch record. The tank 
holding time after 
CIP/SIP is qualified. The 
product holding time in 
the transference tank is 
validated for a certain 
time (can be up to 72 h). 
4 12 48 
Med RISK 
further test 
required 
Validation study for 
product transference. 
Bulk holding time in 
transference tank. 
C13 
Bulk Solution 
Sampling 
Incompatibility 
with containers; 
Contamination; 
use of non-
dedicated or 
disposable 
materials; 
incorrect 
sampling 
procedures; 
product 
oxidation 
High results 
for related 
substances 
and low assay 
results; high 
bioburden; 
products cross 
contamination
; assay OOS. 
Results not 
representative 
of bulk 
solution (false 
results). Batch 
failure. 
2 
Incorrect sampling 
procedures. Wrong 
sampling 
containers used.  
High headspace 
oxygen inside the 
sampling container 
that can react with 
the product. 
2 
Surfaces compatibility 
studies are made for 
Hikma products and 
requested for clients' 
products; Operators are 
trained in compounding 
GMPs every year; for 
oxygen sensitive 
products the sampling 
container has to be 
totally filled l no avoid 
headspace. 
2 4 8 
No RISK no 
further test is 
required 
Batch sampled in 
different containers for 
compatibility surfaces 
studies. 
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